

PRODUCT MONOGRAPH

PrTAXOTERE®

(docetaxel for injection)

Concentrated Solution

80 mg/2.0 mL

20 mg/0.5 mL

Manufacturer's Standard

ATC code: L01C D02

Antineoplastic Agent

sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval (Québec) H7V 0A3

Date of Revision:
June 15, 2020

Submission Control No.: 237181

s-a version 17.0 dated June 15, 2020

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS	5
ADVERSE REACTIONS	11
DRUG INTERACTIONS.....	30
DOSAGE AND ADMINISTRATION.....	31
OVERDOSAGE	36
ACTION AND CLINICAL PHARMACOLOGY.....	36
STORAGE AND STABILITY	37
SPECIAL HANDLING INSTRUCTIONS.....	38
DOSAGE FORMS, COMPOSITION AND PACKAGING.....	38
PART II: SCIENTIFIC INFORMATION.....	40
PHARMACEUTICAL INFORMATION	40
CLINICAL TRIALS	41
DETAILED PHARMACOLOGY.....	49
TOXICOLOGY	52
REFERENCES.....	57
PART III: CONSUMER INFORMATION.....	59

PrTAXOTERE®

(docetaxel for injection)

Concentrated Solution

80 mg/2.0 mL

20 mg/0.5 mL

Manufacturer's Standard

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Nonmedicinal Ingredients
Intravenous infusion	Concentrate for Injection 80 mg/2.0 mL and 20 mg/0.5 mL	Polysorbate 80
	Diluent	Ethanol 95% v/v / water for injection (13/87 w/w)

INDICATIONS AND CLINICAL USE

Breast Cancer:

TAXOTERE® (docetaxel for injection) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

The effectiveness of TAXOTERE in combination with doxorubicin and cyclophosphamide (TAC) is based on improved disease free survival and overall survival in comparison to the combination of fluorouracil, doxorubicin and cyclophosphamide (FAC). However, the positive benefit for TAC in patients with 4+ nodes was not fully demonstrated since the differences in disease-free survival (DFS) and overall survival (OS) between TAC and FAC were not statistically significant in the 4+ nodes stratum.

TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic breast cancer. TAXOTERE, in combination with doxorubicin as first line therapy, should be reserved for patients with potentially life threatening disease (such as visceral or lung metastatic disease).

TAXOTERE in combination with Xeloda[®] (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Non-Small Cell Lung Cancer:

TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives.

Ovarian Cancer:

TAXOTERE is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy.

Prostate Cancer:

TAXOTERE in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer.

Squamous Cell Carcinoma of the Head and Neck:

TAXOTERE is indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

TAXOTERE should be administered under the supervision of a physician experienced in the use of antineoplastic agents.

CONTRAINDICATIONS

- TAXOTERE (docetaxel for injection) is contraindicated in:
 - patients who have a history of hypersensitivity reactions to TAXOTERE or to other drugs formulated with polysorbate 80,
 - pregnant women, (see WARNINGS AND PRECAUTIONS, Special Population, Pregnant Women subsection)
 - women who are breast-feeding, (see WARNINGS AND PRECAUTIONS, Special Population, Nursing Women subsection) and
 - patients with severe liver impairment.
- TAXOTERE should not be used in patients with baseline neutrophil counts of <1,500 cells/mm³.

Contraindications for other drugs also apply when combined with docetaxel:

- Contraindications for Xeloda[®] (capecitabine) also apply to the capecitabine plus TAXOTERE combination (Please refer to Xeloda[®] Product Monograph).
- Contraindications to prednisone also apply to the combination with TAXOTERE (Please refer to Product Monograph for prednisone).
- Contraindications to doxorubicin and cyclophosphamide also apply to their combination with TAXOTERE (Please refer to Product Monographs for doxorubicin and cyclophosphamide).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- **TAXOTERE should be administered under the supervision of a physician experienced in the use of antineoplastic agents (see INDICATIONS AND CLINICAL USE).**
- **There is a higher risk of developing severe adverse reactions including toxic death and fatal gastrointestinal hemorrhage in patients with hepatic impairment (see Hepatic section below). TAXOTERE should not be used in patients with total bilirubin > ULN or AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN.**
- **TAXOTERE therapy should not be given to patients with neutrophil counts of less than 1,500 cells/mm³ (see Hematologic section below).**
- **Fatal cases of enterocolitis, including ischemic colitis, colitis and neutropenic enterocolitis have been reported (see Gastrointestinal Reactions below).**
- **Severe hypersensitivity reactions, with a potential fatal outcome, requiring immediate discontinuation of TAXOTERE may occur. Patients should be closely monitored (see Hypersensitivity Reactions below).**
- **Treatment related second primary malignancies, including acute myeloid leukemia, may occur. No studies have been conducted to assess the carcinogenic potential of TAXOTERE (see Carcinogenesis and Mutagenesis section below).**

General

All patients should be premedicated with an oral corticosteroid such as dexamethasone 16 mg per day (e.g., 8 mg BID) for 3 days starting one day prior to TAXOTERE administration to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions.

The pretreatment regimen for prostate cancer (given the concurrent use of prednisone or prednisolone) is oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the TAXOTERE infusion (see DOSAGE AND ADMINISTRATION, Premedication section).

Concomitant use of TAXOTERE and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. In patients receiving treatment with TAXOTERE, close monitoring for toxicity and a TAXOTERE dose reduction could be considered if systemic

administration of a potent CYP3A4 inhibitor cannot be avoided (see DRUG INTERACTIONS section).

There are no clinical data with a dose adjustment in patients receiving strong CYP3A4 inhibitors. Based on extrapolation from a pharmacokinetic study with ketoconazole in 7 patients, consider a 50% docetaxel dose reduction if patients require co-administration of a strong CYP3A4 inhibitor.

The amount of ethanol in TAXOTERE may be harmful in patients suffering from alcoholism and should also be taken into account in children and in high-risk groups such as patients with liver disease or epilepsy. Consideration should be given to possible effects on the central nervous system. The amount of ethanol in TAXOTERE may impair the ability to drive or use machines (see Neurologic below).

The amount of ethanol in TAXOTERE may alter the effects of other medicinal products (see DRUG INTERACTIONS).

Carcinogenesis and Mutagenesis

Second Primary Malignancies

Second primary malignancies have been reported in patients treated with docetaxel (as monotherapy and when given in combination with anticancer treatments known to be associated with second primary malignancies). Second primary malignancies (including acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma and renal cancer) may occur several months or years after docetaxel-containing therapy.

Treatment related acute myeloid leukemia (AML) may occur. In the adjuvant breast cancer trial (TAX316) at a median follow-up of 96 months, AML was reported in 4 of 744 patients who received TAXOTERE, doxorubicin and cyclophosphamide (TAC) and in 1 of 736 patients who received 5-fluorouracil, doxorubicin and cyclophosphamide (FAC). Myelodysplastic syndrome (MDS) was reported in 2 of 744 patients who received TAC and in 1 of 736 patients who received FAC.

In patients treated with TAXOTERE, doxorubicin and cyclophosphamide (TAC) as adjuvant therapy for breast cancer, the risk of delayed myelodysplasia or myeloid leukemia requires hematological follow-up (see ADVERSE REACTIONS). All patients treated with docetaxel-containing regimens should be monitored for second primary malignancies (see ADVERSE REACTIONS).

TAXOTERE has been shown to be mutagenic in the *in vitro* chromosome aberration test in CHO-K₁ cells and in the *in vivo* micronucleus test in the mouse.

The carcinogenic potential of TAXOTERE has not been studied. However, given that TAXOTERE is unequivocally genotoxic, it should be presumed to be a human carcinogen (see Part II, TOXICOLOGY).

Cardiovascular

Ventricular arrhythmia (including sometimes fatal ventricular tachycardia, fibrillation and extrasystole) has been reported in patients treated with docetaxel in combination regimens including, but not limited to, doxorubicin, 5-fluorouracil and/or cyclophosphamide (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions). Baseline cardiac assessment is recommended.

Endocrine and Metabolism

Tumor Lysis Syndrome

Tumor lysis syndrome, including fatal cases, has been reported in patients treated with docetaxel. Patients at risk of tumor lysis syndrome (i.e. those with renal impairment, hyperuricemia, bulky tumor) should be closely monitored in order to properly manage this syndrome. Correction of dehydration and treatment of high uric acid levels are recommended prior to initiation of treatment.

Fluid Retention

Severe fluid retention has been reported following TAXOTERE therapy. Therefore, patients should be premedicated with oral corticosteroids prior to each TAXOTERE administration to reduce the incidence and severity of fluid retention (see DOSAGE AND ADMINISTRATION section). Patients with preexisting severe fluid retention such as pleural effusion, pericardial effusion and ascites should be closely monitored from the first dose for the possible exacerbation of the effusions.

Gastrointestinal Reactions

Caution is recommended for patients with neutropenia, who are particularly at risk for developing gastrointestinal complications. Enterocolitis could develop at any time, and could lead to death as early as on the first day of onset. Patients should be closely monitored for early manifestations of serious gastrointestinal toxicity (see Hematologic below and ADVERSE REACTIONS, Post-Market Adverse Drug reactions).

Hematologic

Neutropenia is the most frequently reported adverse event. Neutrophil nadirs occurred at a median of 7 days but this interval may be shorter in heavily pretreated patients. TAXOTERE therapy should not be administered until the neutrophil count is over 1,500 cells/mm³. In order to monitor the occurrence of myelotoxicity, it is recommended that frequent blood cell counts be performed on all patients receiving TAXOTERE. Patients should not be retreated with

subsequent cycles of TAXOTERE until neutrophils recover to a level of $>1,500$ cells/mm³. In cases of severe neutropenia (<500 cells/mm³) for seven days or more during a course of TAXOTERE therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate systematic measures are recommended (see DOSAGE AND ADMINISTRATION section).

Hepatic

In patients treated with TAXOTERE who have total bilirubin greater than the upper limit of normal (ULN) or transaminase (ALT and/or AST) greater than 1.5 times the ULN concurrent with alkaline phosphatase greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal hemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia. The severe or life-threatening complications have been reported in these patients at subclinical doses. TAXOTERE should not be used in patients with total serum bilirubin $> ULN$ or in patients with ALT and/or AST $> 1.5 \times ULN$ concurrent with alkaline phosphatase $> 2.5 \times ULN$. Liver function tests (LFTs) should be measured at baseline and before each cycle.

The amount of ethanol in TAXOTERE should be taken into account when given to patients with hepatic impairment (see Neurologic section below).

Hypersensitivity Reactions

Severe hypersensitivity reactions characterized by severe hypotension, bronchospasm, generalized rash/erythema or very rarely fatal anaphylaxis have been reported in patients who received premedication. These reactions resulted in immediate discontinuation in approximately 0.4% (5 of 1260) of patients. Severe symptoms resolve after discontinuation of the infusion and administration of appropriate therapy.

Patients should be observed closely for hypersensitivity reactions especially during the first and second infusions. Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of TAXOTERE, thus facilities for the treatment of hypotension and bronchospasm should be available. Severe reactions require immediate discontinuation of TAXOTERE and aggressive therapy. Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOTERE. If minor reactions such as flushing or localized skin reactions occur, therapy with TAXOTERE does not have to be discontinued. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of TAXOTERE (see DOSAGE AND ADMINISTRATION section).

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a potentially fatal hypersensitivity reaction to TAXOTERE.

Neurologic

The development of severe peripheral neurotoxicity is infrequent and requires a reduction in dose (see DOSAGE AND ADMINISTRATION section). If symptoms persist, treatment should be discontinued.

Alcohol content: Cases of alcohol intoxication have been reported with some formulations of docetaxel due to the alcohol content. Each intravenous administration of TAXOTERE (at 100 mg/m² with 2-vial formulations) delivers approximately 1.0 g/m² of alcohol. The alcohol content in a dose of docetaxel should be taken into account for patients in whom alcohol intake should be avoided or minimized, including patients with hepatic impairment or epilepsy. Some medications, such as CNS depressants, pain relievers and sleep aids may interact with the alcohol in the docetaxel infusion and exacerbate depression or worsen the intoxicating effects (see DRUG INTERACTIONS). Monitor patients for signs of alcohol intoxication during and after treatment. Patients should be advised not to drive or use machines immediately after the infusion.

Ophthalmologic

Cystoid macular edema (CME) has been reported in patients treated with TAXOTERE, as well as with other taxanes (see ADVERSE REACTIONS – Post-Market Adverse Drug Reactions section). Patients with impaired vision during TAXOTERE treatment should undergo a prompt and complete ophthalmologic examination. In case CME is diagnosed, TAXOTERE treatment should be discontinued and if necessary appropriate treatment initiated. CME is usually reversible upon discontinuation of taxane therapy.

Renal

A dose reduction of Xeloda[®] (capecitabine) to 75% is recommended when used in combination with docetaxel in patients with moderate renal impairment (Please refer to Xeloda[®] Product Monograph).

Respiratory

Acute respiratory distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung disease, lung infiltration, pulmonary fibrosis, respiratory failure, and radiation recall phenomena have been reported, and have occasionally been associated with fatal outcome. Cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.

Skin

Localized erythema of the extremities (palm of the hands and soles of the feet) with edema, followed by desquamation has been observed. In case of severe skin toxicity during a course of TAXOTERE therapy, a reduction in dose for subsequent courses of therapy is recommended (see DOSAGE AND ADMINISTRATION section).

Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported in association with docetaxel treatment. Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. In case SCARs are observed, permanent treatment discontinuation should be considered.

Special Populations

Pregnant Women: TAXOTERE may cause fetal harm when administered to a pregnant woman. There is no information on the use of TAXOTERE during pregnancy. No evidence of teratogenic effect was found when TAXOTERE was administered at 1.8 or 1.2 mg/m²/day, in rats or rabbits, respectively. However, TAXOTERE has been shown to be both embryotoxic and fetotoxic in rabbits and rats – causing intrauterine mortality, reduced fetal weight and fetal ossification delays – and to reduce fertility in rats. These effects are consistent with maternal toxicity. As with other cytotoxic drugs, TAXOTERE may cause fetal harm when administered to pregnant women. Therefore, TAXOTERE must not be used during pregnancy. Women of childbearing age and receiving TAXOTERE should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur. Should TAXOTERE be used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.

Nursing Women: It is not known whether TAXOTERE is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from TAXOTERE, breastfeeding must be discontinued during TAXOTERE therapy.

Pediatrics: The safety and effectiveness of TAXOTERE in children have not been established.

Geriatrics: Those with poor performance status, or otherwise non-life threatening indolent disease (such as relatively asymptomatic metastatic disease limited to the bone) should be considered as possible candidates for less toxic therapies prior to consideration of a TAXOTERE based therapy.

An analysis of safety data in patients equal or greater than 60 years of age showed an increase in the incidence of treatment-related grade 3 and 4 adverse events when treated with TAXOTERE in combination with Xeloda[®]. Treatment-related serious adverse events and early withdrawals from treatment due to adverse events were lower in patients of less than 60 years of age.

Of the 332 patients treated with TAXOTERE every three weeks plus prednisone in the prostate cancer study (TAX327), 208 patients were 65 years of age or greater and 67 patients were older than 75 years. In patients treated with TAXOTERE every three weeks, the following treatment emergent adverse events (TEAEs) occurred at rates $\geq 10\%$ higher in patients 65 years of age or greater compared to younger patients: anemia (71% vs. 59%), infection (37% vs. 24%), nail changes (34% vs. 23%), anorexia (21% vs. 10%), weight loss (15% vs. 5%) respectively.

ADVERSE REACTIONS

CLINICAL TRIAL EXPERIENCE

TAXOTERE (DOCETAXEL FOR INJECTION) AS A SINGLE AGENT

Adverse Drug Reaction Overview

Two thousand one hundred and six (2106) patients received an initial dose of 100 mg/m² of TAXOTERE as a single agent over a one-hour infusion independently of the pre-medication for the treatment of various tumor types. The patients were enrolled in 40 clinical trials conducted in North America and Europe (breast carcinoma, n= 991; non-small cell lung cancer, n= 634). The following table lists adverse reaction data from 2045 patients with normal LFTs at baseline and 61 patients with elevated LFTs at baseline.

Additionally, 96 patients enrolled in 3 clinical trials received an initial dose of 100 mg/m² of TAXOTERE as a single agent over a one-hour infusion every 3 weeks for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

These reactions were considered possibly or probably related to TAXOTERE. The safety profile is generally similar in all patients whether they were treated for breast carcinoma or for other tumor types (e.g. ovarian cancer).

Clinical Trials Adverse Drug Reactions

Table 1 - Summary of Adverse Events in Patients Receiving TAXOTERE as a Single Agent

	TAXOTERE as Single Agent (100 mg/m ²)		
	Various Tumor Types Including: Breast Carcinoma, Non-Small Cell Lung Cancer and Ovarian Cancer		Squamous Cell Carcinoma of the Head and Neck
	Normal LFTs* at Baseline N = 2045 (%)	Elevated LFTs at Baseline N = 61 (%)	Normal LFTs* at Baseline N = 96 (%)
ALOPECIA	75.8	62.3	85.4
ARTHRALGIA			
- All Grades	9.2	6.6	5.5 [n=54]
- Severe	0.6	0	0 [n=54]
ASTHENIA			
- All Grades	61.8	52.5	63.5
- Severe	12.8	24.6	20.8
CUTANEOUS			
- All Grades	47.6	57.4	39.6
- Grades III-IV	4.8	9.8	3.1
FEVER IN ABSENCE OF INFECTION			
- All Grades	32.1	41.0	29.2 [n=65]
- Grades III-IV	2.1	8.2	1.5 [n=65]
FLUID RETENTION			
- All Grades	47.0	54.1	28.1
- Severe	6.9	9.8	4.2

	TAXOTERE as Single Agent (100 mg/m ²)		
	Various Tumor Types Including: Breast Carcinoma, Non-Small Cell Lung Cancer and Ovarian Cancer		Squamous Cell Carcinoma of the Head and Neck
	Normal LFTs* at Baseline N = 2045 (%)	Elevated LFTs at Baseline N = 61 (%)	Normal LFTs* at Baseline N = 96 (%)
GASTROINTESTINAL			
Nausea (All)	38.9	37.7	19.8 [‡]
-Severe (Grades III-IV)	3.9	4.9	-
Diarrhea (All)	39.0	32.8	15.6
-Severe (Grades III-IV)	4.7	4.9	-
Vomiting (All)	22.3	23.0	15.6 [‡]
-Severe (Grades III-IV)	2.7	4.9	-
HYPERSENSITIVITY REACTIONS			
- All Grades	21.0	19.7	16.7
- Severe	4.2	9.8	3.1
INFUSION SITE REACTION			
- All Grades	4.4	3.3	-
MYALGIA			
- All Grades	18.9	16.4	16.7 [n=66]
- Severe	1.5	1.6	0 [n=66]
NAIL CHANGES			
- All Grades	30.6	23.0	28.1
- Severe	2.5	4.9	-
NEUROMOTOR			
- All Grades	13.8	6.6	7.1 [n=41]
- Grades III-IV	3.6	1.6	1.0 [n=41]
NEUROSENSORY			
- All Grades	49.3	34.4	37.9 [n=66]
- Grade III	4.3	0	3.1 [n=66] [#]
NON-SEPTIC DEATH	0.3	6.6	NR
SEPTIC DEATH	1.4	3.3	1.0
STOMATITIS			
- All Grades	41.7	49.2	29.2
- Grades III-IV	5.5	13.1	6.3
<p>*Normal liver function tests (LFTs): transaminase ≤ 1.5 times upper limit of normal or alkaline phosphatase ≤ 2.5 times upper limit of normal or isolated elevations of transaminase or alkaline phosphatase up to 5 times upper limit of normal.</p> <p># Includes 2 patients who were counted as having peripheral neuropathy.</p> <p>[‡] Includes one patient with combined nausea/vomiting.</p> <p>NR = Not reported.</p>			

Table 2- Summary of Haematologic Adverse Events in Patients Receiving TAXOTERE as a Single Agent

	TAXOTERE as Single Agent (100 mg/m ²)		
	Various Tumor Types Including: Breast Carcinoma, Non-Small Cell Lung Cancer and Ovarian Cancer		Squamous Cell Carcinoma of the Head and Neck
	Normal LFTs* at Baseline N = 2045 (%)	Elevated LFTs at Baseline N = 61 (%)	Normal LFTs* at Baseline N = 96 (%)
Anemia < 11 g/dL	90.4	91.8	90.8 [n=65]
- Grades III- IV < 8 g/dL	8.8	31.2	0 [n=65]
Febrile Neutropenia	11.0	24.5	24.0 [§]
Infection			
- All Grades	21.6	32.8	-
- Grades III-IV	6.1	16.4	-
Leukopenia < 4,000 cells/mm ³	95.6	98.3	86.3 [n=95]
- Grade IV < 1,000 cells/mm ³	31.6	46.6	20.0 [n=95]
Neutropenia < 2,000 cells/mm ³	95.5	96.4	95.4 [n=65]
- Grade IV < 500 cells/mm ³	75.4	87.5	69.2 [n=65]
Thrombocytopenia < 100,000 cells/mm ³	8.0	24.6	3.1 [n=65]
- Grade IV	0.5	4.9	-

*Normal liver function tests (LFTs): transaminase ≤ 1.5 times upper limit of normal or alkaline phosphatase ≤ 2.5 times upper limit of normal or isolated elevations of transaminase or alkaline phosphatase up to 5 times upper limit of normal.

§ Includes 16 patients who were counted as having febrile leukopenia requiring hospitalization (defined as WBC count ≤ 1000/mcL associated with fever ≥38°C requiring hospitalization).

Cardiovascular: Hypotension occurred in 3% of the patients and required therapy in 0.5% of the patients treated with TAXOTERE as a single agent for various tumor types. Dysrhythmia occurred in 2% of the patients and was severe in 0.4% of the patients. Clinically meaningful events occurred in less than 2% of patients. These events included: heart failure (0.3%), tachycardia (1.4%), and hypertension (1.6%).

Cutaneous: Cutaneous reactions have been observed in 48% of the patients treated with TAXOTERE as a single agent for various tumor types. These reactions were characterized by a rash, including localized eruptions mainly on feet and hands (including severe hand and foot syndrome), but also on arms, face or thorax. They were frequently associated with pruritus. Eruptions generally occurred within one week following the TAXOTERE infusion, resolved before the next infusion, and were not disabling.

Severe symptoms such as eruptions followed by desquamation occurred less frequently (5 %). These reactions rarely led to interruption or discontinuation of TAXOTERE treatment.

Severe nail disorders occurred in ≤ 3% of the patients treated with TAXOTERE as a single agent. These reactions were characterized by hypo- or hyperpigmentation, and infrequently onycholysis and pain.

Alopecia was observed in 76% of patients treated with TAXOTERE as a single agent for various tumor types (0.5% severe), and in 85% of patients treated for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Fluid Retention: Fluid retention which includes edema, and less frequently, pleural effusion, ascites, pericardial effusion, and weight gain, usually begins at the lower extremities and may become generalized with a weight gain of 3 kg or more. Fluid retention is cumulative in incidence and severity (see WARNINGS AND PRECAUTIONS section).

The incidence of fluid retention in patients treated with TAXOTERE as a single agent and without premedication was 81.6%; of these 22.4% were severe. In patients treated for various tumor types and premedicated for 3 days with oral corticosteroids, the incidence of fluid retention was 64.1% (6.5% were severe). Fluid retention was reported in 24% for patients treated for recurrent and/or metastatic SCCHN. Below is a table describing the effect on fluid retention with corticosteroid premedication (see DOSAGE AND ADMINISTRATION section for premedication regimen).

Table 3 - Effects of Corticosteroid Premedication on the Incidence of Fluid Retention

	Incidence	Severe
Without premedication	81.6%	22.4%
3-Day Premedication*	64.1%	6.5%

* Fluid retention adverse reactions have been obtained from 92 patients treated with TAXOTERE as single agent, 100 mg/m², from a retrospective analysis on the 3 day premedication regimen

In patients treated by docetaxel as single agent, at 100 mg/m², the median cumulative dose to treatment discontinuation was more than 1,000 mg/m² and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks). The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m²) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m²); however, it has been reported in some patients during early courses of therapy. Fluid retention has not been accompanied by oliguria or hypotension, and was slowly reversible after TAXOTERE treatment was stopped.

Gastrointestinal: Nausea (39%), diarrhea (39%), and vomiting (22%), were observed in patients treated with TAXOTERE as a single agent for various tumor types. They were less frequent in patients treated for recurrent and/or metastatic SCCHN (20%, 16% and 16% respectively). These reactions were generally mild to moderate. Severe gastrointestinal reactions generally occurred in less than 5% of the cases reported. Stomatitis was reported by 42% and by 29% of patients treated for various tumor types and for recurrent and/or metastatic SCCHN, respectively. Other gastrointestinal events included anorexia, taste perversion, constipation, abdominal pain, gastrointestinal bleeding and esophagitis.

Hematologic: Bone marrow suppression and other hematologic adverse reactions to TAXOTERE include neutropenia, febrile neutropenia, thrombocytopenia and anemia, have been reported.

Neutropenia was the most frequent adverse reaction associated with TAXOTERE; it was reversible and not cumulative. The median time to nadir was 7 days, while the median duration of severe neutropenia (< 500 cells/mm³) was 7 days. Severe neutropenia occurred in 75% of the patients treated with TAXOTERE as a single agent for various tumor types and 69% in patients with recurrent and/or metastatic SCCHN.

When treated with TAXOTERE as a single agent, fever was associated with neutropenia (< 500 cells/mm³) in 11% of the patients with normal liver function (3% of the cycles) treated for various tumor types and in 24% of patients treated for recurrent and/or metastatic SCCHN. The incidence of severe infections associated with neutrophil counts < 500 cells/mm³ was 6% of the patients (1.3% of the cycles). Infectious episodes which included sepsis and pneumonia occurred in 22% of the patients (6% of the cycles) and were fatal in approximately 1.7% of patients treated with TAXOTERE as a single agent for various tumor types. Septic death was reported less frequently (1%) in patients treated for recurrent and/or metastatic SCCHN.

Thrombocytopenia ($< 100,000$ cells/mm³) has been reported in 8% of the patients treated with TAXOTERE as a single agent for various tumor types and 3.1% of patients treated for recurrent and/or metastatic SCCHN. Bleeding episodes were reported in 1% of the patients; this was associated with severe thrombocytopenia ($< 50,000$ cells/mm³) in only two patients. A fatal gastrointestinal hemorrhage due to thrombocytopenia was reported in one patient.

Anemia (< 11 g/dL) was observed in 90% of the patients treated with TAXOTERE as a single agent and was severe (< 8 g/dL) in 9% of the cases. It was not reported in patients treated for recurrent and/or metastatic SCCHN.

Hepatic: Increases in alanine transferase (ALT), aspartate transferase (AST), bilirubin, and alkaline phosphatase which were greater than 2.5 times the upper limit of normal were observed in less than 5% of patients treated with TAXOTERE as a single agent for various tumor types.

Hypersensitivity Reactions: Hypersensitivity reactions occurred in 21% of the patients treated with TAXOTERE as a single agent for various tumor types and in 17% of patients treated for recurrent and/or metastatic SCCHN. The reactions occurred generally within a few minutes following the start of the infusion of TAXOTERE and were usually mild to moderate. The most frequent minor manifestations were flushing, rash with or without pruritus, chest tightness, back pain, dyspnea, drug fever, or chills.

Severe reactions characterized by hypotension, bronchospasm, or generalized rash/erythema have occurred within a few minutes following the initiation of infusion of TAXOTERE as a single agent. Severe symptoms were observed in 4% of the patients treated for various tumor types; however, 1.2% (25 of 2045) had immediate discontinuation of treatment. All hypersensitivity reactions resolved after discontinuation of the infusion and appropriate therapy.

Infusion Site Reactions: Infusion site reactions occurred in 6% of the patients treated with TAXOTERE as a single agent for various tumor types and were generally mild. These reactions included skin sensitivities such as hyperpigmentation, inflammation, local erythema, redness or

dryness of the skin, or swelling of the vein. Phlebitis or extravasation was observed less frequently.

Neurologic: Neurosensory symptoms characterized by paresthesia, dysesthesia or pain (including burning sensation) were reported in 49% of patients treated with TAXOTERE as a single agent for various tumor types and in 38% of patients treated for recurrent and/or metastatic SCCHN. Severe reactions were observed in less than 4% of the patients.

Neuromotor events (mainly characterized by weakness) were reported in 14% of patients treated with TAXOTERE as a single agent for various tumor types. These reactions were severe in 4% of patients.

When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued (see DOSAGE AND ADMINISTRATION and Dose Adjustments sections).

Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 81 days from onset (range 0 to 741 days).

Other: Asthenia was reported by 62% of all patients and was considered severe in 13% of patients treated for various tumor types and in 21% of patients treated for recurrent and/or metastatic SCCHN. Arthralgias (5.5% to 9%) and myalgias (19%) were reported by patients but were generally considered to be mild to moderate.

Respiratory: Dyspnea has been reported.

TAXOTERE (DOCETAXEL FOR INJECTION) IN COMBINATION

Adverse Drug Reaction Overview

The percentage of events related to combination therapy might be different from those related to monotherapy with TAXOTERE. Please refer to the following tables for adverse drug reactions related to different combination therapies.

Clinical Trials Adverse Drug Reactions

- *Adjuvant Treatment of Breast Cancer – TAXOTERE in Combination with Doxorubicin and Cyclophosphamide*

Adverse Drug Reactions during treatment: The following table presents the treatment emergent adverse events (TEAEs) possibly or probably related to treatment observed during treatment phase in the TAX316 study in which 744 patients were treated with 75 mg/m² of TAXOTERE every 3 weeks in combination with 50 mg/m² of doxorubicin and 500 mg/m² of cyclophosphamide (TAC regimen) and 736 patients were treated with the combination of 500 mg/m² of 5-fluorouracil, 50 mg/m² of doxorubicin, and 500 mg/m² of cyclophosphamide every 3 weeks (FAC regimen).

Table 4 - Clinically Important Treatment Related Adverse Events in Patients in the TAX 316 Study

	TAXOTERE (75 mg/m ²) in combination with Doxorubicin (50 mg/m ²) and Cyclophosphamide (500 mg/m ²) [TAC regimen] N = 744 (%)		5-fluorouracil (500 mg/m ²) in combination with Doxorubicin (50 mg/m ²) and Cyclophosphamide (500 mg/m ²) [FAC regimen] N = 736 (%)	
Adverse Event	Any	Grade 3 / 4	Any	Grade 3 / 4
Body as a whole				
Abdominal pain	7.3	0.5	3.3	0.0
Asthenia	79.2	11.0	69.4	5.2
Fever in absence of infection	43.1	1.2	13.2	0.0
Cardiovascular System				
Cardiac dysrhythmias	3.9	0.1	2.9	0.3
Hypotension	1.5	0.0	0.5	0.0
Phlebitis	0.7	0.0	0.4	0.0
Syncope	0.5	0.0	0.4	0.0
Vasodilatation	20.3	0.9	15.9	0.4
Digestive System				
Anorexia	19.9	2.2	16.4	1.2
Constipation	22.6	0.4	21.5	1.2
Diarrhea	30.9	3.2	23.5	1.0
Nausea	80.4	5.1	87.4	9.5
Stomatitis	69.1	7.1	52.6	2.0
Vomiting	42.6	4.3	58.2	7.3
Hematologic				
Anemia	91.5	4.3	71.7	1.6
Febrile neutropenia*	24.7	N/A	2.5	N/A
Lymphedema	0.3	0.0	0.0	0.0
Neutropenia	71.4	65.5	82.0	49.3
Thrombocytopenia	39.4	2.0	27.7	1.2
Immune System				
Hypersensitivity reactions	10.5	1.1	2.2	0.0
Infections and Infestations				
Infection	27.2	3.2	17.4	1.4
Neutropenic infection**	12.1	N/A	6.3	N/A
Metabolic and Nutritional Disorders				

	TAXOTERE (75 mg/m²) in combination with Doxorubicin (50 mg/m²) and Cyclophosphamide (500 mg/m²) [TAC regimen] N = 744 (%)		5-fluorouracil (500 mg/m²) in combination with Doxorubicin (50 mg/m²) and Cyclophosphamide (500 mg/m²) [FAC regimen] N = 736 (%)	
Adverse Event	Any	Grade 3 / 4	Any	Grade 3 / 4
Peripheral edema	26.7	0.4	7.2	0.0
Weight gain or loss	15.2	0.3	9.2	0.0
Musculoskeletal System				
Arthralgia	15.1	0.4	5.7	0.3
Myalgia	22.8	0.8	8.0	0.0
Nervous System				
Neuro-cerebellar	1.1	0.1	0.8	0.0
Neuro-cortical	2.8	0.3	3.9	0.3
Neuropathy motor	2.8	0.0	1.5	0.0
Neuropathy sensory	23.8	0.0	7.9	0.0
Respiratory System				
Cough	3.1	0.0	2.2	0.1
Skin and Appendages				
Alopecia	97.7	N/A	97.1	N/A
Nail disorders	18.4	0.4	13.9	0.1
Skin toxicity	18.4	0.7	10.9	0.3
Special Senses				
Conjunctivitis	4.6	0.3	6.0	0.1
Lacrimation disorder	9.8	0.1	6.4	0.0
Taste perversion	27.4	0.7	15.1	0.0
Urogenital System				
Amenorrhea	57.6	N/A	48.1	N/A

* Febrile neutropenia was defined as grade ≥ 2 NCI term “fever in absence of infection” (oral temperature $\geq 38.1^{\circ}\text{C}$) concomitant (i.e., measured within 24 hours) with grade 4 neutropenia ($\text{ANC} < 0.5 \times 10^9/\text{L}$), requiring IV antibiotics and/or hospitalization.

** Neutropenic infection was defined as grade ≥ 2 NCI term “infection” concomitant (i.e., measured within 24 hours) with grade ≥ 3 neutropenia ($\text{ANC} < 1.0 \times 10^9/\text{L}$).

During the treatment period, of the 744 patients treated with TAC in the TAX316 study, 33.1% experienced severe TEAEs possibly or probably related to treatment compared to 22.1% of the 736 patients treated with FAC. Dose reductions due to hematologic toxicity occurred in 1% of cycles in the TAC arm compared to 0.1% of cycles in the FAC arm. Six percent of patients treated with TAC discontinued treatment due to adverse events, compared to 1.1% treated with FAC; fever in the absence of infection and allergy being the most common reasons for

withdrawal among TAC-treated patients. Two TAC-treated patients died within 30 days of their last study treatment; 1 death was considered to be related to study drug. Two FAC-treated patients died within 30 days of their last study treatment; 1 death was considered to be related to study drug.

Adverse Drug Reactions during follow-up: The follow-up period was defined as the period of time beginning after the end of chemotherapy visit and ending at the end of the 10-year follow-up period. A final analysis of the TAX316 study was performed, with an actual median follow-up of 96 months. Patients were followed until the initiation of further anti-cancer therapy, until lost to follow-up, or until the end of the 10-year follow-up period.

- *Persistent TEAEs:* The most common TEAEs that were first documented during the treatment period and persisted into the follow-up period, regardless of causal relationship, were alopecia (TAC: 687 patients; FAC: 645 patients), asthenia (TAC: 236 patients; FAC: 180 patients), amenorrhea (TAC: 202 patients; FAC: 136 patients), hot flush (TAC: 129 patients; FAC: 109 patients), edema peripheral (TAC: 119 patients; FAC: 23 patients), nail disorder (TAC: 106 patients; FAC: 79 patients), weight increased (TAC: 89 patients; FAC: 61 patients), and peripheral sensory neuropathy (TAC: 84 patients; FAC: 15 patients). Among TEAEs that persisted into the follow-up period in >1% of patients, the majority of events resolved.
- *Ongoing TEAEs:* TEAEs that were reported as ongoing at the end of the follow-up period include amenorrhea (TAC: 121 patients; FAC: 86 patients), alopecia (TAC: 29 patients; FAC: 16 patients), asthenia (TAC: 29 patients; FAC: 16 patients), hot flush (TAC: 38 patients; FAC: 43 patients), increased weight (TAC: 33 patients; FAC: 25 patients), peripheral sensory neuropathy (TAC: 10 patients; FAC: 2 patients), arthralgia (TAC: 8 patients; FAC: 2 patients), lymphedema (TAC: 6 patients; FAC: 1 patient), myalgia (TAC: 6 patients; FAC: 0 patients) and dyspnea (TAC: 4 patients; FAC: 0 patients).
- *AEs that started or worsened during follow-up:* During the follow-up period, 13.8% of TAC patients and 11.3% of FAC patients experienced at least one grade 3-4 adverse event that started or worsened during the follow-up period. The most common severe adverse events that started or worsened during follow-up include cardiac failure congestive (TAC: 26 patients; FAC: 17 patients), hot flush (TAC: 25 patients; FAC: 10 patients) and increased weight (TAC: 9 patients; FAC: 7 patients). The most common AEs that started or worsened during the follow-up period include hot flush (TAC: 177 patients; FAC: 200 patients), skin disorder (TAC: 151 patients; FAC: 157 patients) and amenorrhea (TAC: 79 patients; FAC: 99 patients). AEs that started or worsened during follow-up and remained ongoing at the end of the follow-up include amenorrhea (TAC: 46 patients; FAC: 50 patients), hot flush (TAC: 46 patients; FAC: 64 patients), weight increased (TAC: 21 patients; FAC: 20 patients), lymphedema (TAC: 15 patients; FAC: 7 patients), telangiectasia (TAC: 8 patients; FAC: 9 patients), pulmonary fibrosis (TAC: 10 patients; FAC: 9 patients), menstruation irregular (TAC: 7 patients; FAC: 8 patients), edema peripheral (TAC: 8 patients; FAC: 6 patients), and edema (TAC: 3 patients; FAC: 0 patients).

Fever and Infection: Treatment related fever in the absence of infection was seen in 43.1% (Gr 3/4: 1.2%) of TAC-treated patients and in 13.2% (Gr 3/4: 0.0%) of FAC-treated patients. Treatment related infection was seen in 27.2% (Gr 3/4: 3.2%) of TAC-treated patients and in

17.4% (Gr 3/4: 1.4%) of FAC-treated patients. There were no septic deaths in either treatment arm. G-CSF was used as treatment or secondary prophylaxis in 29.2% of TAC-treated patients compared to 5.6% of FAC-treated patients.

Gastrointestinal events: In addition to gastrointestinal events reflected in the above table, 7 patients in the TAC treatment arm and 1 patient in the FAC treatment arm were reported to have treatment related colitis/enteritis/large intestine perforation. Two of the 7 TAC-treated patients required treatment discontinuations.

Cardiovascular events: During the treatment period, more cardiovascular events were reported in the TAC arm than in the FAC arm: treatment related dysrhythmias, all grades (3.9% vs 2.9%), treatment related hypotension, all grades (1.5% vs 0.5%) and clinically significant treatment-emergent congestive heart failure (CHF), cardiac function grade 3-4 (1.6% vs 0.5%). One TAC-treated patient died due to heart failure. While left ventricular ejection fraction (LVEF) was measured at baseline as a study requirement in the TAX316 study, repeat measurements were not performed unless considered clinically relevant by the investigator. Of the patients with repeat LVEF assessment, 14/66 (21%) in the TAC treatment group and 4/48 (8.3%) in the FAC treatment group were reported to have LVEF declines to levels below the lower limit of normal. Twenty-six patients in the TAC group developed CHF during the study period, with most cases reported in the follow-up period. CHF lead to death in 2 TAC patients and in 4 FAC patients during follow-up period. The risk of CHF is higher in the TAC group in the first year.

Acute Myeloid Leukemia/Myelodysplastic Syndrome: At a median follow-up time of 96 months, 4 of 744 patients treated with TAC and 1 of the 736 patients treated with FAC were diagnosed with AML. MDS was reported in 2 TAC patients and in 1 FAC patients. In two of the TAC-associated AML cases, abnormalities of chromosome 11 were present. In one of the TAC-associated MDS case, the chromosome abnormality t(11; 14)(q23;q24) was present. One TAC patient died due to AML during the follow-up period.

▪ ***Locally-Advanced and/or Metastatic Breast Cancer – TAXOTERE in Combination with Doxorubicin***

The following two tables show data from a combination study with TAXOTERE and doxorubicin in patients with locally advanced and/or metastatic breast cancer. In this study, 258 patients received 75 mg/m² of TAXOTERE with 50 mg/m² of doxorubicin.

Table 5 - Summary of Adverse Events Possibly or Probably Related to Study Treatment in Patients with Locally-Advanced and/or Metastatic Breast Cancer Receiving TAXOTERE in Combination with Doxorubicin

	TAXOTERE in combination (75 mg/m ²) with Doxorubicin (50 mg/m ²) N = 258 (%)
ALOPECIA	94.6
ARTHRALGIA	
- All Grades	5.4
- Severe	0.4
ASTHENIA	
- All Grades	54.7
- Severe	8.1
CUTANEOUS	
- All Grades	13.6
- Grades III-IV	0
FEVER IN ABSENCE OF INFECTION	
- All Grades	50.4*
- Grades III-IV	0.4*
FLUID RETENTION	
- All Grades	35.7
- Severe	1.2
GASTROINTESTINAL	
Nausea (All)	64.0
-Severe (Grades III-IV)	5.0
Diarrhea (All)	45.7
-Severe (Grades III-IV)	6.2
Vomiting (All)	45.0
-Severe (Grades III-IV)	5.0
HYPERSENSITIVITY REACTIONS	
- All Grades	4.7
- Severe	1.2
INFUSION SITE REACTION	
- All Grades	3.5
MYALGIA	
- All Grades	8.5
- Severe	0
NAIL CHANGES	
- All Grades	20.2
- Severe	0.4
NEUROMOTOR	
- All Grades	2.3
- Grades III-IV	0.4
NEUROSENSORY	
- All Grades	30.2
- Grade III	0.4
NON-SEPTIC DEATH	2.3
SEPTIC DEATH	0
STOMATITIS	
- All Grades	58.1
- Grades III-IV	7.8
* In study TAX 306 (n=213), it included febrile neutropenia	

Table 6 - Summary of Haematologic Adverse Events Possibly or Probably Related to Study Treatment in Patients with Locally-Advanced and/or Metastatic Breast Cancer Receiving TAXOTERE in Combination with Doxorubicin

	TAXOTERE in combination (75 mg/m ²) with Doxorubicin (50 mg) N = 258 (%)
Anemia < 11 g/dL	96.1
- Grades III- IV < 8 g/dL	9.4
Febrile Neutropenia	34.1
Infection	
- All Grades	35.3
- Grades III-IV	7.8
Leukopenia < 4,000 cells/mm ³	99.6
- Grade IV < 1,000 cells/mm ³	53.5
Neutropenia < 2,000 cells/mm ³	99.2
- Grade IV < 500 cells/mm ³	91.7
Thrombocytopenia < 100,000 cells/mm ³	28.1
- Grade IV	0.8

▪ ***Locally-Advanced and/or Metastatic Breast Cancer – TAXOTERE in Combination with Capecitabine***

The following text and table provide data for the combination study with TAXOTERE and capecitabine in 506 patients with locally advanced and/or metastatic breast cancer. In the TAXOTERE-capecitabine combination arm (251 patients), the treatment was capecitabine administered orally 1250 mg/m² twice daily as intermittent therapy (2 weeks of treatment followed by one week without treatment) for at least 6 weeks and TAXOTERE administered as a 1 hour intravenous infusion at a dose of 75 mg/m² on the first day of each 3 week cycle for at least 6 weeks. In the monotherapy arm (255 patients), TAXOTERE was administered as a one-hour intravenous infusion at a dose of 100 mg/m² on the first day of each 3 week cycle for at least 6 weeks. The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm. A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse events. The percentage of patients requiring dose reductions due to adverse events were 65% in the combination arm and 36% in the monotherapy arm. The hospitalization rate for treatment-related adverse events was 28.7% in the combination arm and 26.3% in the monotherapy arm.

Table 7 - Adverse Events Considered Related to Treatment in ≥ 5% of Patients Participating in the Combination Study of TAXOTERE and Capecitabine in Patients with Locally-Advanced and/or Metastatic Breast Cancer

Adverse Event	Capecitabine 1250 mg/m ² /bid (Intermittent Regimen) with TAXOTERE 75 mg/m ² /3 weeks (N=251)			TAXOTERE 100 mg/m ² /3 weeks (N=255)		
	NCIC Grade					
Body System /Adverse Event	Total %	Grade 3 %	Grade 4 %	Total %	Grade 3 %	Grade 4 %
GI						
Stomatitis	67	17.1	0.4	43	4.7	-
Diarrhea	64	13.5	0.4	45	5.4	0.4
Nausea	43	6.4	-	35	2	-
Vomiting	33	3.6	0.8	22	0.8	-
Constipation	14	1.2	-	12	-	-
Abdominal pain	14	2	-	9	0.8	-
Dyspepsia	12	-	-	5	0.4	-
Abdominal pain upper	9	-	-	6	-	-
Dry mouth	5	0.4	-	4	-	-
Skin and Subcutaneous						
Hand-and-Foot Syndrome	63	24.3	-	8	1.2	-
Alopecia	41	6	-	42	6.7	-
Nail disorder	14	2	-	15	-	-
Dermatitis	8	-	-	9	0.8	-
Rash erythematous	8	0.4	-	4	-	-
Nail discolouration	6	-	-	4	0.4	-
Onycholysis	5	1.2	-	5	0.8	-
Pruritis	2	-	-	5	-	-
General						
Pyrexia	21	0.8	-	29	0.4	-
Asthenia	23	3.2	0.4	22	5.5	-
Fatigue	21	4.4	-	25	5.1	-
Weakness	13	1.2	-	9	2	-
Pain in limb	9	0.4	-	8	0.4	-
Lethargy	6	-	-	5	1.2	-
Pain	6	-	-	2	-	-
Neurological						
Taste disturbance	15	0.4	-	14	0.4	-
Headache	7	0.4	-	8	-	-
Paraesthesia	11	0.4	-	15	0.8	-
Dizziness	9	-	-	6	0.4	-
Insomnia	4	-	-	5	0.4	-
Peripheral neuropathy	5	-	-	10	0.8	-
Hypoaesthesia	4	-	-	7	0.4	-
Metabolism						
Anorexia	12	0.8	-	10	0.8	-
Appetite decreased	10	-	-	4	-	-
Dehydration	8	2	-	5	0.4	0.4
Eye						
Lacrimation increased	12	-	-	5	-	-

Adverse Event	Capecitabine 1250 mg/m ² /bid (Intermittent Regimen) with TAXOTERE 75 mg/m ² /3 weeks (N=251)			TAXOTERE 100 mg/m ² /3 weeks (N=255)		
Body System /Adverse Event	NCIC Grade					
	Total %	Grade 3 %	Grade 4 %	Total %	Grade 3 %	Grade 4 %
Musculoskeletal						
Arthralgia	11	1.2	-	18	2.4	-
Myalgia	14	1.6	-	24	2	-
Back pain	7	0.8	-	6	0.8	-
Cardiac						
Edema lower limb	14	0.8	-	12	1.2	-
Edema NOS	4	-	-	5	-	0.8
Edema peripheral	4	-	-	5	0.4	-
Hematologic						
Neutropenia	17	4.8	10.8	16	2.7	11.8
Neutropenic fever	16	2.8	13.1	21	4.7	16.1
Anaemia	13	2.8	0.8	11	3.9	-
Respiratory						
Dyspnea	7	0.8	-	9	0.4	-
Cough	6	0.4	-	9	-	-
Sore throat	11	1.6	-	7	0.4	-
Epistaxis	5	0.4	-	5	-	-
Infections and Infestations						
Oral candidiasis	6	0.4	-	7	0.4	-

Cutaneous: Hand-and-foot syndrome was more common in patients in the combination therapy arm than in the TAXOTERE monotherapy arm (63% vs. 8%).

Hematology: In 251 patients who received TAXOTERE in combination with capecitabine, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia and 9.6% had grade 3 or 4 anemia.

Hyperbilirubinemia: In 251 patients who received a combination of capecitabine and TAXOTERE, grade 3 and 4 hyperbilirubinemia occurred in 6.8% (n=17) and 2% (n=5), respectively.

Table 8 - Patients with Laboratory Abnormalities Participating in the Combination Study of TAXOTERE with Capecitabine in Patients with Locally-Advanced and/or Metastatic Breast Cancer

Adverse Event	Capecitabine 1250 mg/m ² /bid (Intermittent Regimen) with TAXOTERE 75 mg/m ² /3 weeks (N=251)			TAXOTERE 100 mg/m ² /3 weeks (N=255)		
	Total %	Grade 3 %	Grade 4 %	Total %	Grade 3 %	Grade 4 %
Hematologic						
Leukopenia	91	37	24	88	42	33
Neutropenia/Granulocytopenia	86	20	49	87	10	66
Thrombocytopenia	41	2	7	23	1	2
Anemia	80	7	3	83	5	<1
Lymphocytopenia	99	48	41	98	44	40
Hepatobiliary						
Hyperbilirubinemia	20	7	2	6	2	2

Shown below by body system are the adverse events in < 5% of patients in the overall clinical trial safety database of 251 patients reported as related to the administration of capecitabine in combination with TAXOTERE and that were clinically at least remotely relevant. In parentheses is the incidence of grade 3 and 4 occurrences of each adverse event.

Cardiovascular: supraventricular tachycardia (0.39), hypotension (1.20), venous phlebitis & thrombophlebitis (0.39), blood pressure increase (0.39), postural hypotension (0.80)

Gastrointestinal: hemorrhoids (0.39), ileus (0.39), necrotizing enterocolitis (0.39), esophageal ulcer (0.39), hemorrhagic diarrhea (0.80)

General: rigors (0.39), injection site infection (0.39), neuralgia (0.39)

Hematologic: agranulocytosis (0.39), prothrombin decreased (0.39)

Hepatobiliary: jaundice (0.39), abnormal liver function tests (0.39), hepatic failure (0.39), hepatic coma (0.39), hepatotoxicity (0.39)

Immune System: hypersensitivity (1.20)

Infection: neutropenic sepsis (2.39), lower respiratory tract infection nos (0.39), pharyngitis (0.39), otitis media (0.39), sepsis (0.39), bronchopneumonia (0.39)

Neurological: ataxia (0.39), syncope (1.20), taste loss (0.80), polyneuropathy (0.39), migraine (0.39)

Renal: renal failure (0.39)

▪ **Prostate Cancer – TAXOTERE in Combination with Prednisone or Prednisolone**

The following data are based on the experience of 332 patients, who were treated with TAXOTERE 75 mg/m² every 3 weeks in combination with prednisone or prednisolone 5 mg orally twice daily.

Table 9 - Clinically Important Treatment-Related Adverse Events in Patients with Prostate Cancer who Received TAXOTERE in Combination with Prednisone or Prednisolone (TAX 327)

Adverse Event	TAXOTERE 75 mg/m ² every 3 weeks with prednisone (or prednisolone) 5 mg twice daily (N=332)	
Body System /Adverse Event	NCI Grade	
	Total %	Grade 3/4 %
Alopecia	65.1	--
Allergic reactions	6.9	0.6
Anemia	66.5	4.9
Anorexia	12.7	0.6
Arthralgia	3.0	0.3
Cardiac left ventricular function decrease	3.9	0.3
Cough	1.2	0.0
Diarrhea	24.1	1.2
Dyspnea	4.5	0.6
Epistaxis	3.0	0.0
Fatigue	42.8	3.9
Febrile neutropenia	2.7	--
Fluid retention	24.4	0.6
Infection	12.0	3.3
Myalgia	6.9	0.3
Nail changes	28.3	--
Nausea	35.5	2.4
Neuropathy motor	3.9	0.0
Neuropathy sensory	27.4	1.2
Neutropenia	40.9	32.0
Rash/Desquamation	3.3	0.3
Stomatitis/Pharyngitis	17.8	0.9
Taste disturbance	17.5	--
Tearing	9.3	0.6
Thrombocytopenia	3.4	0.6
Vomiting	13.3	1.2

Of the 332 patients treated with TAXOTERE every three weeks in the prostate cancer study (TAX 327), 208 patients were 65 years of age or greater and 67 patients were older than 75 years. In patients treated with TAXOTERE every three weeks, the incidence of anemia, infection, nail changes, anorexia, weight loss, regardless of relationship to TAXOTERE,

occurred at rates $\geq 10\%$ higher in patients who were 65 years of age or greater compared to younger patients. Fatigue, all grades, was one of the most commonly reported TEAEs (regardless of relationship to TAXOTERE in patients treated with TAXOTERE every three weeks, but grade 3-4 were experienced in only 1.6% of subjects < 65 years old, 6.3% in those ≥ 65 years, and 10.4% in those ≥ 75 years old. Similarly diarrhea, all grades, was also commonly reported, but the incidence of grade 3-4 diarrhea was much lower for each age category, 1.6%, 2.4% and 3.0% respectively. There was a similar pattern for the incidence of infection grade 3-4, in the three age categories the incidence was 4.0%, 6.7%, and 9.0%, respectively.

POST-MARKET ADVERSE DRUG REACTIONS

Cardiovascular:

Cases of venous thromboembolic events and myocardial infarction have been reported.

Ventricular arrhythmia (including sometimes fatal ventricular tachycardia, fibrillation and extrasystole) has been reported in patients treated with TAXOTERE in combination regimens including, but not limited to, doxorubicin, 5-fluorouracil and/or cyclophosphamide (see WARNINGS AND PRECAUTIONS, Cardiovascular).

Cutaneous:

Cases of cutaneous lupus erythematosus, bullous eruptions such as erythema multiforme, severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis have been reported with docetaxel. Scleroderma-like changes usually preceded by peripheral lymphedema have been reported with TAXOTERE. In some cases, multiple factors such as concomitant infections, concomitant medications and underlying disease may have contributed to the development of these effects. Cases of permanent alopecia have been reported.

Fluid Retention:

Dehydration and pulmonary edema have been reported.

Gastrointestinal:

Cases of gastrointestinal perforation; dehydration as a consequence of gastrointestinal events, including enterocolitis and gastrointestinal perforation. Enterocolitis, including ischemic colitis, colitis and neutropenic enterocolitis have been reported; some cases resulted in fatal outcome.

Cases of ileus and intestinal obstruction have been reported.

General disorders and administration site conditions:

Injection site recall reactions (recurrence of skin reaction at a site of previous extravasation following administration of TAXOTERE at a different site) have been observed.

Hematologic:

Cases of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in association with TAXOTERE when used in combination with other chemotherapy

agents and/or radiotherapy. Disseminated intravascular coagulation (DIC), often in association with sepsis, or multiorgan failure, has been reported.

Hepatic:

Cases of hepatitis and hepatic failure, sometimes fatal primarily in patients with pre-existing liver disorders, have been reported.

Hypersensitivity Reactions:

Cases of severe hypersensitivity reactions/anaphylactic shock have been reported. Cases of anaphylactic shock with a fatal outcome have been reported in patients who received premedication.

Hypersensitivity reactions/anaphylactic shock have been reported with TAXOTERE in patients who previously experienced hypersensitivity reactions/anaphylactic shock to paclitaxel.

Metabolism and Nutrition:

Cases of electrolyte imbalance have been reported. Serious cases of hyponatraemia have been reported, some associated with dehydration, vomiting and pneumonia. Hypokalaemia (including serious cases), hypomagnesaemia, and hypocalcaemia were observed, usually in association with gastrointestinal disorders and in particular with diarrhea. Tumor lysis syndrome, sometimes fatal, has been reported.

Musculoskeletal:

Myositis has been reported with docetaxel.

Neoplasms benign, malignant and unspecified (including cysts and polyps):

Second primary malignancies (frequency not known) including non-Hodgkin lymphoma and renal cancer, have been reported in association with docetaxel when used as a monotherapy and in combination with other anticancer treatments known to be associated with second primary malignancies. Acute myeloid leukemia and myelodysplastic syndrome have been reported (frequency uncommon) in pivotal clinical studies in breast cancer with TAC or FAC regimens.

Neurologic:

Cases of convulsion or transient loss of consciousness have been observed with TAXOTERE administration. These reactions sometimes appear during the infusion of the drug.

Ophthalmologic:

Cases of lacrimation with or without conjunctivitis have been reported and cases of lacrimal duct obstruction resulting in excessive tearing have been reported primarily in patients receiving other anti-tumor agents concomitantly.

Cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during drug infusion and in association with hypersensitivity reactions have been reported. These were reversible upon discontinuation of the infusion.

Cases of cystoid macular edema (CME) have been reported in patients treated with TAXOTERE (see WARNINGS AND PRECAUTIONS section). Based on a number of documented reports, including literature cases, an association between CME and TAXOTERE is considered to be reasonably well established. Features specific to this clinical entity (docetaxel-induced CME) may include an absence of vascular leakage with no other precipitating factors. Certain cases of CME were reversible upon discontinuation of TAXOTERE therapy, in some cases with initiation of appropriate treatment, while in other cases no further treatment was required.

Other:

Generalised and localised pain including chest pain without any cardiac or respiratory involvement.

Ototoxicity and Hearing disorders:

Ear and labyrinth disorders include cases of ototoxicity, hearing disorders and/or hearing loss which have been reported, including cases associated with other ototoxic drugs.

Renal:

Cases of renal insufficiency, including renal failure, have been reported in clinical trials with docetaxel, and they are typically associated with concomitant nephrotoxic drugs.

Respiratory:

Acute respiratory distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung disease, lung infiltration, pulmonary fibrosis, respiratory failure and radiation recall phenomena have been reported, and have occasionally been associated with fatal outcome. Cases of radiation pneumonitis have been reported in patients receiving concomitant radiotherapy.

DRUG INTERACTIONS

Docetaxel is a CYP3A4 substrate. *In vitro* studies have shown that the metabolism of TAXOTERE may be modified by the concomitant administration of compounds, that induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) CYP3A4 such as rifampin, cyclosporine, terfenadine, ketoconazole, erythromycin and troleandomycin. As a result, caution should be exercised when treating patients with these drugs as concomitant therapy since there is a potential for a significant interaction.

The exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4. Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel. Concomitant use of TAXOTERE and drugs that inhibit CYP3A4 (such as ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) may increase adverse reactions as a result of increased exposure to docetaxel and should be avoided. In patients receiving treatment with TAXOTERE, close monitoring for toxicity and a TAXOTERE dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.

Each intravenous administration of TAXOTERE (at 100 mg/m² with 2-vial formulations) delivers approximately 1.0 g/m² of alcohol. The alcohol content may alter the effects of other medicinal products. Central nervous system depression may be exacerbated and occur at a lower blood alcohol levels when TAXOTERE is taken along with other CNS depressants (e.g., diazepam or similar benzodiazepines). Some medications (e.g., pain relievers, sleep aids) may worsen alcohol intoxicating effects.

TAXOTERE is highly protein bound (> 95%). Although the possible *in vivo* interaction of TAXOTERE with concomitantly administered medication has not been investigated formally, *in vitro* interactions with tightly protein-bound drugs, such as erythromycin, diphenhydramine, propranolol, propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of TAXOTERE. TAXOTERE did not influence the binding of digoxin.

The effect of daily oral prednisone administration on the pharmacokinetics of TAXOTERE administered with dexamethasone premedication prior to infusion has been evaluated in 42 patients treated for prostate cancer. No effect of prednisone on the pharmacokinetics of TAXOTERE was observed.

There is no evidence of a pharmacokinetic interaction between TAXOTERE and doxorubicin. The pharmacokinetics of docetaxel given in combination with doxorubicin and cyclophosphamide, have been studied in 30 patients treated for advanced breast cancer. There was no evidence of a pharmacokinetic interaction between the three drugs.

DOSAGE AND ADMINISTRATION

Recommended Dose

Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, and Squamous Cell Carcinoma of the Head and Neck: The recommended dosage of TAXOTERE (docetaxel for injection) is 100 mg/m² administered as a one-hour infusion every 3 weeks. When used in combination, TAXOTERE is administered at the recommended dosage of 75 mg/m².

Prostate Cancer: The recommended dosage of TAXOTERE is 75 mg/m² administered as a one-hour infusion every 3 weeks. Concomitant treatment with prednisone or prednisolone 5 mg orally twice daily is administered continuously.

Adjuvant Treatment of Operable Node-Positive Breast Cancer: The TAXOTERE (docetaxel for injection) dose is 75 mg/m² administered 1-hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² every 3 weeks for 6 courses (see also Dosage Adjustment).

Premedication

Premedication Regimen (see below for prostate cancer): In order to reduce the incidence and severity of fluid retention, all patients should be pretreated with oral corticosteroids. The

recommended premedication should consist only of oral corticosteroids, such as dexamethasone 16 mg per day (e.g. 8 mg BID), for 3 days starting one day prior to each TAXOTERE administration. Antihistamines have not been shown to be useful in controlling fluid retention.

Premedication Regimen for Prostate Cancer: For prostate cancer, given the concurrent use of prednisone or prednisolone, the recommended premedication regimen is oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the TAXOTERE infusion.

Other Dosing Considerations

Prophylactic Use of Antibiotics: In order to reduce the incidence of febrile neutropenia and infections, the prophylactic use of antibiotics is recommended to patients treated for head and neck cancer. The treatment should consist of oral fluoroquinolone antibiotics, or equivalent oral or intravenous antibiotics, for 10 days starting on day 5 of each cycle of TAXOTERE administration.

Prophylactic Use of G-CSF: Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities. See Dosing Adjustment section. In addition to G-CSF, the prophylactic use of antibiotics may provide additional benefit.

Geriatrics: Based on the population pharmacokinetics, there are no special instructions for the use in the elderly (see WARNINGS AND PRECAUTIONS section).

Dosing Adjustment

Patients with Neutropenia, Cutaneous Reactions or Peripheral Neuropathy: Careful monitoring of neutrophil counts is an essential part of TAXOTERE therapy. TAXOTERE should not be administered until the neutrophil count is at least 1,500 cells/mm³. Patients who experience febrile neutropenia, severe neutropenia (neutrophil <500 cells/mm³ for more than one week), severe or cumulative cutaneous reaction, or severe neurosensory signs and/or symptoms during TAXOTERE therapy should have the dosage of TAXOTERE reduced from 100 mg/m² to 75 mg/m². When TAXOTERE is given in combination, the dose of TAXOTERE should be reduced from 75 mg/m² to 60 mg/m². If the patient continues to experience these reactions at 60 mg/m², the treatment should be discontinued. Alternatively, prophylactic G-CSF may be used in patients with either prior febrile neutropenia or severe infection in order to maintain dose intensity (see WARNINGS AND PRECAUTIONS section).

Patients who receive adjuvant therapy for breast cancer and who experience febrile neutropenia should receive G-CSF in all subsequent cycles. Patients who continue to experience this reaction should remain on G-CSF and have their TAXOTERE dose reduced to 60 mg/m². If G-CSF is not used, the TAXOTERE dose should be reduced from 75 to 60 mg/m². Patients who experience grade 3 or 4 stomatitis should have their dose decreased from 75 to 60 mg/m².

Patients with Hepatic Impairment: TAXOTERE should not be used in patients with serum bilirubin > ULN. Also, TAXOTERE should not be used in patients who have ALT and/or AST > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN.

The amount of ethanol in TAXOTERE should be taken into account when given to patients with hepatic impairment (see WARNINGS AND PRECAUTIONS).

Concomitant use with a potent CYP3A4 inhibitor: if systemic administration of a potent CYP3A4 inhibitor cannot be avoided, a dose reduction of TAXOTERE should be considered and close monitoring for toxicity is recommended (see WARNINGS AND PRECAUTIONS, General and DRUG INTERACTIONS sections).

TAXOTERE in Combination with Capecitabine:

Table 10 - Recommended Dose Modifications for Combination Therapy with Capecitabine

	Grade 2	Grade 3	Grade 4
1st appearance	Interrupt treatment until resolved to grade 0-1 then continue at same doses with prophylaxis where possible	Grade 3 at time TAXOTERE treatment due: interrupt treatment and delay for a maximum of two weeks until grade 0-1 then continue at 75% of original capecitabine dose and at 55 mg/m ² of TAXOTERE with prophylaxis where possible. If no recovery to grade 0-1 within two weeks delay, patient will stop TAXOTERE therapy but may restart capecitabine at 75% of original capecitabine dose when grade 0-1 Grade 3 occurring between cycles with recovery to grade 0-1 by the time the next treatment due: continue at 75% of original capecitabine dose and at 55 mg/m ² of TAXOTERE with prophylaxis where possible	Discontinue capecitabine and TAXOTERE treatment unless treating physician considers it to be in the best interest of the patient to continue with capecitabine monotherapy at 50% of original dose
2nd appearance of same toxicity	Interrupt treatment until resolved to grade 0-1, then continue at 75% of original capecitabine dose and at 55 mg/m ² of TAXOTERE	Discontinue TAXOTERE treatment and interrupt capecitabine treatment until resolved to grade 0-1, then continue at 50% of original capecitabine dose	
3rd appearance of same toxicity	Interrupt treatment until resolved to grade 0-1, then continue at 50% of original capecitabine dose and discontinue TAXOTERE	Discontinue treatment	
4th appearance of same toxicity	Discontinue treatment		

Administration

Precautions: TAXOTERE must be administered intravenously. It is extremely important that the intravenous needle or catheter be properly positioned before any TAXOTERE is injected. Leakage into surrounding tissue during intravenous administration of TAXOTERE may cause considerable irritation, local tissue necrosis and/or thrombophlebitis. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should be introduced into another vein.

Injection site recall reactions (recurrence of skin reaction at a site of previous extravasation following administration of TAXOTERE at a different site) have been observed.

Please refer to the SPECIAL HANDLING INSTRUCTIONS section as well.

Reconstitution of Solutions

Preparation and Administration Precautions: TAXOTERE concentrated solution requires dilution prior to administration. Please follow the preparation instructions provided below.

A) Preparation of the Premix Solution:

1. If the vials are stored under refrigeration, allow the required number of TAXOTERE concentrate and diluent vials to stand at room temperature for approximately 5 minutes.
2. Using a syringe fitted with a needle, aseptically withdraw the entire contents of the solvent for TAXOTERE by partially inverting the vial. Inject the entire contents of the syringe into the corresponding TAXOTERE concentrate vial.
3. Remove the syringe and needle and mix manually by repeated inversions for at least 45 seconds. Do not shake.
4. The TAXOTERE premix solution (10 mg docetaxel/mL) should be clear; however, there may be some foam on top of the solution due to the polysorbate 80. Allow the premix solution to stand for 5 minutes to allow any foam to dissipate. It is not required that all foam dissipate prior to continuing the preparation process.

After reconstitution, the TAXOTERE premix is stable for 8 hours at room temperature or between 2 and 8°C (see STORAGE AND STABILITY section).

B) Preparation of the Infusion Solution:

1. Aseptically withdraw the required amount of TAXOTERE premix solution (10 mg docetaxel/mL) with a calibrated syringe and inject the required volume of premix solution into a 250 mL infusion bag or bottle of either 0.9% Sodium Chloride solution or 5% Dextrose solution to produce a final concentration of 0.3 to 0.74 mg/mL. If a dose greater than 200 mg of TAXOTERE is required, use a larger volume of the infusion vehicle so that a concentration of 0.74 mg/mL TAXOTERE is not exceeded.
2. Thoroughly mix the infusion by manual rotation.
3. As with all parenteral products, TAXOTERE should be inspected visually for particulate matter or discoloration prior to administration whenever the solution and container permit. If the TAXOTERE for Injection premix solution or infusion solution is not clear or appears to have precipitation, the solution should be discarded.

TAXOTERE infusion solution should be aseptically administered intravenously as a 1-hour infusion under ambient room temperature and lighting conditions.

Contact of the undiluted concentrate with plasticized PVC equipment or devices used to prepare solution for infusion is not recommended. In order to minimize patient exposure to plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, TAXOTERE infusion solution should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets.

OVERDOSAGE

There is no known antidote for TAXOTERE (docetaxel for injection) overdose. In case of overdose, the patient should be kept in a specialized unit where vital functions can be closely monitored and supportive treatment administered as necessary. Anticipated complications of overdose include: bone marrow suppression, peripheral neurotoxicity, and mucositis. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed.

There were a few reports of overdose. One patient received 150 mg/m² and the other received 200 mg/m² as one-hour infusion. Some patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

TAXOTERE (docetaxel for injection) is an antineoplastic agent, which acts by disrupting the microtubular network in cells that is essential for vital mitotic and interphase cellular functions. TAXOTERE promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. TAXOTERE binds to free tubulin thereby decreasing the critical intracellular concentration of tubulin. The promoted polymerization of microtubules leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, resulting in the inhibition of mitosis in cells. The binding of TAXOTERE to microtubules does not alter the number of protofilaments in the bound microtubules; in that, it differs from other spindle poisons.

TAXOTERE was found to be cytotoxic *in vitro* against various murine and human tumor cell lines, and against freshly excised human tumor cells in clonogenic assays.

In addition, TAXOTERE was found to be active on a number of cell lines overexpressing the p-glycoprotein, which is encoded by the multidrug resistant gene.

Pharmacokinetics

At doses of 70-115 mg/m², the kinetic profile of TAXOTERE is dose independent and consistent with a three-compartment pharmacokinetic model, with half lives for the α , β and γ phases of 4 min, 36 min and 11.1 h, respectively.

TAXOTERE is more than 95% protein bound, to α 1-acid glycoprotein, albumin and lipoproteins, with high binding affinity for α 1- acid glycoprotein. Dexamethasone does not affect the protein binding of TAXOTERE.

Based on *in vitro* studies, isoenzymes of the cytochrome P450-3A subfamily appear to be involved in docetaxel oxidative metabolism of the tert-butyl ester group.

Mean values for total body clearance and steady state volume of distribution were 21 L/h/m² and 113 L, respectively.

A study in cancer patients administered ¹⁴C-docetaxel revealed that docetaxel was eliminated in the urine and feces within seven days. The urinary and fecal excretion accounted for about 6% and 75% of the administered radioactivity, respectively. About 80% of the radioactivity recovered in feces is excreted during the first 48 hours as one major inactive metabolite and 3 minor inactive metabolites and 2.7% of unchanged drug.

A population pharmacokinetic analysis has been performed in patients receiving TAXOTERE. Pharmacokinetic parameters estimated by the model were very close to those estimated from Phase I studies. The pharmacokinetics of TAXOTERE were not altered by the age or sex of the patient, but by liver hepatic impairment. In a study in patients with varying degrees of hepatic impairment (due to malignancies), decreased clearance (by 47% on average) of docetaxel was observed in patients with hepatic impairment (bilirubin > ULN or ALT/AST > 1.5 but ≤ 5 x ULN concurrent with alkaline phosphatase > 2.5 but ≤ 5 x ULN) when compared to those with normal hepatic function. Serum free docetaxel was not measured in this study.

The effect of daily oral prednisone administration on the pharmacokinetics of TAXOTERE administered with dexamethasone premedication prior to infusion has been evaluated in 42 patients treated for prostate cancer. No effect of prednisone on the pharmacokinetics of TAXOTERE was observed.

STORAGE AND STABILITY

Stability

Unopened vials of TAXOTERE (docetaxel for injection) are stable until the expiration date indicated on the package when stored between 2° and 25°C and protected from light. Freezing does not adversely affect the product.

Storage

Store the unopened vials between 2°-25°C. Retain in the original package to protect from bright light.

TAXOTERE premix solution (10 mg docetaxel/mL) should be used as soon as possible after preparation. However the chemical and physical stability of the premix solution has been demonstrated stable for 8 hours when stored either between 2 and 8°C or at room temperature.

TAXOTERE infusion solutions, if stored between 2°C and 25°C is stable for 4 hours. Fully prepared TAXOTERE infusion solution (in either 0.9% sodium chloride solution or 5% dextrose solution) should be used within 4 hours (including the 1 hour i.v. administration).

SPECIAL HANDLING INSTRUCTIONS

TAXOTERE is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing TAXOTERE solutions. The use of gloves is recommended.

If TAXOTERE concentrate, premix solution or infusion solution should come into contact with the skin, immediately and thoroughly wash with soap and water. If TAXOTERE concentrate, premix solution, or infusion solution should come into contact with mucosa, immediately and thoroughly wash with water.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published¹⁻⁴. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

DOSAGE FORMS, COMPOSITION AND PACKAGING

TAXOTERE (docetaxel for injection) concentrated solution is a sterile, non-pyrogenic, non-aqueous clear yellow to brownish-yellow viscous solution. Each mL of concentrated solution contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80.

TAXOTERE (docetaxel for injection) concentrated solution requires dilution prior to use (see DOSAGE AND ADMINISTRATION, Reconstitution of solution). A sterile, non-pyrogenic, single-dose diluent is supplied for that purpose. The diluent for TAXOTERE contains ethanol 95% v/v / water for injection (13/87 w/w), and is supplied in 1.5 mL vials (to be used with TAXOTERE 20 mg) and 6.0 mL vials (to be used with TAXOTERE 80 mg).

TAXOTERE (docetaxel for injection) is available in blister packs containing:

- one single-dose vial of concentrated solution and,
- one single-dose vial of diluent

TAXOTERE 20 mg blister pack contains:

- One single-dose vial of concentrated solution of 20 mg/0.5 mL docetaxel (anhydrous) in 0.5 mL polysorbate 80 (Fill: 24.4 mg docetaxel in 0.61 mL polysorbate 80). The overfill ensures that there is a minimal extractable premix volume of 2 mL containing 10 mg/mL docetaxel which corresponds to the labeled amount of 20 mg per vial.
- One single-dose vial of diluent containing 1.98 mL of 13 % w/w ethanol (95%v/v) in Water for Injection. The addition of the entire contents of the diluent vial to the contents of the TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel (and 0.097 g/mL ethanol).

TAXOTERE 80 mg blister pack contains:

- One single-dose vial of concentrated solution of 80 mg/2.0 mL docetaxel (anhydrous) in 2 mL polysorbate 80 (Fill: 94.4 mg docetaxel in 2.36 mL polysorbate 80). The overfill ensures that there is a minimal extractable premix volume of 8 mL containing 10 mg/mL docetaxel which corresponds to the labeled amount of 80 mg per vial.
- One single-dose vial of diluent containing 7.33 mL of 13% w/w ethanol (95%v/v) in Water for Injection The addition of the entire contents of the diluent vial to the contents of the TAXOTERE 80 mg/2 ml concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel (and 0.096 g/mL ethanol).

PART II: SCIENTIFIC INFORMATION


PHARMACEUTICAL INFORMATION

Drug Substance

Common name: Docetaxel

Chemical name: (2R,3S)-N-carboxy-3-phenylisoserine, N-*tert*-butyl ester, 13-ester with 5 β -20-epoxy-1,2 α ,4,7 β ,10 β ,13 α -hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate

Structural formula:



Molecular formula: C₄₃H₅₃NO₁₄ • 3 H₂O

Molecular weight: 861.9

Description: White to almost white powder; the melting point is about 232°C

Solubility: Practically insoluble in water.

CLINICAL TRIALS

Breast Cancer

- Adjuvant Treatment of Breast Cancer

Data from a multicenter unblinded randomized trial support the use of TAXOTERE for the adjuvant treatment of patients with operable node-positive breast cancer. After stratification according to the number of positive lymph nodes (1-3, 4+), 1491 patients were randomized to receive either TAXOTERE 75 mg/m² administered 1-hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² (TAC arm), or doxorubicin 50 mg/m² followed by fluorouracil 500 mg/m² and cyclophosphamide 500 mg/m² (FAC arm). Both regimens were administered once every 3 weeks for 6 cycles. TAXOTERE was administered as a 1-hour infusion, all other drugs were given as IV bolus on day 1. Prophylactic antibiotic therapy was compulsory for subjects treated with TAXOTERE (TAC). Ciprofloxacin was recommended starting day 5 of each cycle. Subjects on FAC were given prophylactic antibiotics for all cycles following an episode of febrile neutropenia or infection. G-CSF was administered as secondary prophylaxis to patients in both treatment groups who experienced febrile neutropenia, prolonged neutropenia or neutropenic infection. In both arms, after the last cycle of chemotherapy, patients with positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years. Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69% of patients who received TAC and 72% of patients who received FAC.

The primary efficacy variable was disease-free survival (DFS) and the main secondary efficacy variable was overall survival. DFS was defined as the time interval between the date of randomization and the date of occurrence of local, regional or metastatic relapse, or the date of second primary cancer or death from any cause, whichever occurs first. After a protocol amendment, further to the Independent Data Monitoring Committee (IDMC) recommendation, subjects who received additional antitumor therapy without evidence of relapse for whatever reason (e.g., intolerance to randomized therapy, withdrawal of consent after randomization) were not to be counted as DFS events. In the original study protocol such subjects were to be counted as events. This involved a total of 81 (5.4%) subjects; 57 (7.7%) subjects randomized to the TAC group and 24 (3.2%) to the FAC group. An interim analysis was planned for 3 years after recruitment of 50% of the subjects using the Peto stopping rule. The final analysis was to be done after 590 events using a 0.05 significance level.

Results presented below are based on a second interim analysis. The first interim analysis (conducted with a median follow-up of 33 months) showed that TAC was associated with a 32% relapse risk reduction (HR 0.68, 95% CI 0.54-0.86) but the corresponding p-value of 0.0011 did not meet the Peto stopping rule boundary which required the p-value to be less than or equal to 0.001. The independent data monitoring committee (IDMC) concluded that the study protocol should be amended to include a second interim analysis after 400 DFS had been recorded

overall, in addition to the protocol-specified final analysis at 590 DFS events. The significance level to be used for the final analysis was revised to 0.048.

Subjects had a median age of 49 years (range 23-70), 49% of subjects were pre-menopausal, and 76% had positive estrogen and/or progesterone receptors. The six cycles of treatment were completed as per protocol in 91.1% and 95.3% of TAC and FAC-treated subjects, respectively.

The second interim analysis was performed with a median follow up of 55 months. Significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated. TAC-treated patients had a 28% relative reduction in the risk of relapse compared to those treated with FAC (hazard ratio=0.72, 95% CI (0.59-0.88) p=0.001, stopping boundary 0.001). This corresponds to an absolute difference in risk of relapse of 8.5% at 4 years. Overall survival was also significantly longer in the TAC arm with TAC-treated patients having a 30% relative reduction in the risk of death compared to FAC (hazard ratio= 0.70, 95% CI (0.53-0.91), p=0.008). This corresponds to an absolute difference in risk of death of 4.0% at 4 years.

Patient subsets according to prospectively defined major prognostic factors were analyzed (see Table 11 below):

Table 11 - Subset Analyses-Adjuvant Breast Cancer Study of TAC vs. FAC (Intent-to-Treat Analysis)

Patient subset	Number of patients	Disease Free Survival		Overall Survival	
		Hazard ratio*	95% CI	Hazard ratio*	95% CI
Number of positive nodes					
Overall	745	0.72	(0.59-0.88)	0.70	(0.53-0.91)
1-3	467	0.61	(0.46-0.82)	0.45	(0.29-0.70)
4+	278	0.83	(0.63-1.08)	0.94	(0.66-1.33)
Receptor status					
Positive	567	0.72	(0.56-0.92)	0.69	(0.48-1.00)
Negative	178	0.69	(0.49-0.97)	0.66	(0.44-0.98)
Her-2 neu status					
Positive	155	0.60	(0.41-0.88)	0.74	(0.45-1.20)
Negative	475	0.76	(0.59-1.00)	0.63	(0.44-0.91)

*a hazard ratio of less than 1 indicates that TAC is associated with a longer disease free survival and overall survival compared to FAC.

The beneficial effect of TAC was seen in both hormone receptor positive and negative patients, and in patients with 1 to 3 positive nodes. However, a beneficial effect of TAC in patients with 4 or more positive lymph nodes was not observed with a median follow-up of 55 months; in the 4+ nodes stratum, the risk reduction in both disease free survival and overall survival associated with TAC was not significantly different from zero.

A final analysis was performed with an actual median follow-up of 96 months. Significantly longer DFS for the TAC arm compared to the FAC arm was demonstrated. TAC-treated patients had a 20.5% relapse risk reduction compared to those treated with FAC (HR = 0.80, 95% CI (0.68-0.93), p = 0.0043). This corresponds to an absolute difference in risk of relapse of 6% at 10 years.

Overall survival at 10 years was also significantly increased in the TAC arm, with the TAC-treated patients having a 25.8 % relative reduction in risk of death compared to FAC (HR = 0.74, 95% CI (0.61-0.90), p=0.002). This corresponds to an absolute reduction of the risk of death of 7% at 10 years. However, the positive benefit for TAC in patients with 4+ nodes was not fully demonstrated since the differences in DFS and OS between TAC and FAC remained not statistically significant in the 4+ nodes stratum at 10 years.

Patient subsets according to prospectively defined major prognostic factors were analyzed (see Table 12 below):

Table 12 - Subset Analyses-Adjuvant Breast Cancer Study of TAC vs. FAC (Intent-to-Treat Analysis) at 96 months follow-up

Patient subset	Number of patients		Disease Free Survival			Overall Survival		
	TAC	FAC	Hazard ratio*	95% CI	P value	Hazard ratio*	95% CI	P value
Number of positive nodes								
Overall	745	746	0.80	(0.68-0.93)	0.0043	0.74	(0.61-0.90)	0.0020
1-3	467	459	0.72	(0.58-0.91)	0.0047	0.62	(0.46-0.82)	0.0008
4+	278	287	0.87	(0.70-1.09)	0.2229	0.87	(0.67-1.12)	0.2746
Receptor status								
Positive	567	565	0.84	(0.70-1.01)		0.76	(0.60-0.96)	
Negative	178	181	0.66	(0.49-0.89)		0.69	(0.49-0.96)	
Her-2 neu status								
Positive	155	164	0.60	(0.43-0.83)		0.66	(0.45-0.96)	
Negative	475	468	0.88	(0.72-1.08)		0.79	(0.61-1.01)	

*a hazard ratio of less than 1 indicates that TAC is associated with a longer disease free survival and overall survival compared to FAC.

- Locally-Advanced or Metastatic Breast Cancer

Six phase II studies were conducted in patients with locally advanced or metastatic breast carcinoma. Among the 325 patients recruited in these studies, 190 patients had progressive disease with anthracycline therapy (anthracycline refractory patients). In these clinical trials, TAXOTERE (docetaxel for injection) was administered at a 100 mg/m² dose given as a one-hour infusion every 3 weeks.

The overall response rate (ORR) for evaluable patients was 43.3% with 3.1% complete responses (CR). The median duration of response of the previously treated and the anthracycline refractory patients was 28 and 26 weeks, respectively. The mean time to progression was 18 weeks for the previously treated and the anthracycline refractory patients. The median survival time of the previously treated and the anthracycline refractory patients was 11 and 10 months, respectively.

Two phase III clinical trials were performed involving a total of 326 metastatic breast cancer patients who previously failed to respond to alkylating agents, and 392 metastatic breast cancer patients who previously failed to respond to anthracycline agents. These patients were randomized to receive either TAXOTERE at the dose of 100 mg/m² administered every 3 weeks or comparator agents.

In the clinical trial with patients who previously failed to respond to alkylating agents, TAXOTERE was compared to doxorubicin (75 mg/m² every 3 weeks). The results demonstrated that TAXOTERE had a statistically significant higher response rate than doxorubicin (52% versus 37.4%, $p = 0.012$), a statistically significant quicker time to onset of antitumor response (12 weeks versus 23 weeks, $p = 0.007$), and also a longer median time to progression (27 weeks versus 23 weeks). The median overall survival was 14.7 months in TAXOTERE patients versus 14.3 months in doxorubicin patients.

Additionally in the clinical trial with patients who previously failed to respond to anthracycline agents, TAXOTERE was compared to the combination of Mitomycin C and Vinblastine (12 mg/m² every 6 weeks and 6 mg/m² every 3 weeks). The results demonstrated that TAXOTERE had a statistically significant higher response rate than Mitomycin C and Vinblastine (33% versus 12.3%, $p < 0.0001$), a statistically significant longer median time to progression (19 weeks versus 11 weeks, $p = 0.0004$) and also a statistically significant longer overall survival (11.4 months versus 8.7 months, $p = 0.01$).

TAXOTERE in Combination with Doxorubicin: One phase III study was conducted in previously untreated patients with metastatic breast cancer. The combination TAXOTERE (75 mg/m²) and doxorubicin (50 mg/m²) was compared to the combination of cyclophosphamide (600 mg/m²) and doxorubicin (60 mg/m²). Both regimens were administered once every 3 weeks. The results demonstrated that TAXOTERE in combination with doxorubicin had a statistically significantly longer median time to progression than the combination cyclophosphamide and doxorubicin (37.3 weeks *versus* 31.9 weeks, $p = 0.0138$), a statistically significant higher overall response rate (59.3% *versus* 46.5%, $p = 0.009$) and also a statistically significantly longer median time to treatment failure (25.6 weeks *versus* 23.7 weeks, $p = 0.0479$). In this trial, the incidence and severity of cardiac toxicity was lower although not statistically significant in the doxorubicin/TAXOTERE arm versus the doxorubicin/cyclophosphamide arm.

Serious adverse events (SAE's) were observed in 55.9% of AT-treated patients compared with 33.8% of AC-treated patients, that is, the incidence of SAE's among AT-treated patients was 1.67 times higher than that among AC-treated patients. The following treatment-related SAE's were more frequent in patients receiving AT than in patients receiving AC: febrile neutropenia (31.5% *versus* 9.0%, 3.5 times more common), vomiting (5.6% *versus* 2.4%, twice as common), diarrhea (4.7% *versus* 0.5%, 10 times more common) and nausea (3.3% *versus* 1.0%, 3 times

more common). Other treatment-related grade 3 / 4 toxicities that were more frequent in AT-treated patients than in AC-treated patients included stomatitis (8.5% *versus* 6.7%, 1.3 times more common), asthenia (8.5% *versus* 2.4%, 3 times more common), pain (2.8% *versus* 0), allergy (1.4% *versus* 0), and anorexia, constipation, nail disorder and peripheral edema (all 0.5% *versus* 0). On the other hand, AC-treated patients had a higher incidence of severe anemia compared with AT-treated patients (15.8% *versus* 8.5%, twice as common), and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% *versus* 2.8%, 1.5 times more common), absolute LVEF decrease of at least 20% (13.1 % *versus* 6.1%, twice as common), absolute LVEF decrease of at least 30% (6.2% *versus* 1.1%, 6 times more common). Toxic death occurred in 1 patient in the AT arm (congestive heart failure) and in 4 patients in the AC arm (1 due to septic shock and 3 due to congestive heart failure).

TAXOTERE in Combination with Capecitabine: TAXOTERE has been evaluated in breast cancer clinical trials in combination with capecitabine (Xeloda). The dose of capecitabine used in combination with TAXOTERE in the phase III clinical trial was based on the results of a phase I study, where a range of doses of TAXOTERE given every 3 weeks in combination with an intermittent regimen of capecitabine were evaluated. The combination dose regimen was selected based on the tolerability profile of the 75 mg/m² every 3 weeks of TAXOTERE in combination with 1250 mg/m² twice daily for 14 days of capecitabine administered every 3 weeks. The approved dose of 100 mg/m² of TAXOTERE administered every 3 weeks was the control arm of the phase III study.

As shown in the following Table, capecitabine in combination with TAXOTERE resulted in statistically significant improvement in time to disease progression, overall survival and objective response rate.

Health Related Quality of Life (HRQoL) was assessed using EORTC QLQ-C30 (version 2) and Breast Cancer Module of the EORTC (BR23). HRQoL was similar in the two treatment groups. Approximately 11% of patients in the combination arm and 10% in the monotherapy arm did not complete a quality of life questionnaire at least once either at baseline or during the treatment phase.

Table 13 - Clinical Trial of TAXOTERE In Combination With Capecitabine in the Treatment of Breast Cancer- Pivotal Study - Combination Therapy

Design Diagnosis	Drug/Dosage	No. Women Enrolled	Results
Open label, randomized, parallel group Females with advanced and/or metastatic breast cancer resistant to or recurring during or after anthracycline-containing therapy or relapsing during or recurring within 2 years of completing anthracycline-containing adjuvant therapy	Capecitabine 2500 mg/m ² /day for 2 weeks with a 1 week rest period in combination with TAXOTERE 75 mg/m ² every 3 weeks	255	<u>Response Rate</u> Combination therapy: 41.6% TAXOTERE monotherapy: 29.7% (p=0.0058)
	TAXOTERE 100 mg/m ² every 3 weeks	256	<u>Time to Disease Progression</u> Combination therapy: 186 days TAXOTERE monotherapy: 128 days (p=0.0001) Hazard Ratio: 0.643 <u>Overall Survival</u> Combination therapy: 442 days TAXOTERE monotherapy: 352 days (p= 0.0126) Hazard Ratio: 0.775

Non-Small Cell Lung Cancer

Monotherapy:

A) Six phase II studies were conducted in patients with locally advanced or metastatic non-small cell lung cancer. A total of 160 patients had received no prior chemotherapy (previously untreated), and 88 patients had received prior platinum-based therapy (previously treated), which included 37 patients who had progressive disease with platinum therapy (platinum refractory). In these clinical trials, TAXOTERE was administered at a 100 mg/m² dose given as a one-hour infusion every 3 weeks.

B) Six additional phase II studies were conducted in 337 patients with naive locally advanced non-small cell lung cancer. In these clinical trials, TAXOTERE was administered at a 100 mg/m² dose given as a one-hour infusion.

C) One phase III study was conducted in 137 patients with naive locally advanced non-small cell lung cancer. In this clinical trial, TAXOTERE was administered at a 100 mg/m² dose given as a one-hour infusion every 3 weeks.

Combination Therapy:

D) Two phase II studies were conducted in 98 patients with naive locally advanced non-small cell lung cancer. In these clinical trials, two different schedules have been tested: TAXOTERE at 75 mg/m² combined with cisplatin at 75 mg/m² given as a one-hour infusion every 3 weeks; and TAXOTERE at 75 mg/m² combined with cisplatin at 100 mg/m² given as a one-hour infusion every 3 weeks for 3 cycles and then every 6 weeks.

E) One phase II study was conducted in 44 patients with naive locally advanced non-small cell lung cancer. In this clinical trial, TAXOTERE was administered at 100 mg/m² on Day 1,

alternating with cisplatin at 120 mg/m² on Day 21, every 6 weeks, with a modified cisplatin dose to 100 mg/m² from the third administration.

The overall response rates, median survival time, median duration of response and median time to progression are represented in the following table:

Table 14 - Clinical Trials of TAXOTERE in Non-Small-Cell Lung Cancer

	Overall Response Rate	Median Survival Time	Median Duration of Response	Median Time to Progression
Monotherapy				
A) Previously untreated patients (N= 160)	19%	8 months	29 weeks	14 weeks
A) Previously treated patients (N=88)	31%	9 months	25 weeks	14 weeks
B) Previously untreated patients (N=337)	20-31%	8.5 - 10 months	5.9 weeks	2-3 months
C) Previously untreated patients (N=137)	18%	6 months	37 weeks	13 weeks
Combination therapy				
D) Previously untreated patients (N=98)	36%	9 months	6 months	4 months
E) Previously untreated patients (N=44)	36%	9 months	10 months	4 months
Overall	18 - 36%	6 - 10 months	6 - 10 months	2 - 4 months

The adverse reaction profile from these naive locally advanced non-small cell lung cancer patients is similar to larger populations studied for metastatic breast cancer (see ADVERSE REACTIONS section).

Ovarian Cancer

TAXOTERE was studied in five phase II clinical trials in patients who were diagnosed with advanced epithelial ovarian cancer and who failed a previous treatment with cisplatin and/or to carboplatin. These patients (n=281) received TAXOTERE 100mg/m² every three weeks as a one-hour infusion.

The overall response rate was 26.7% with a 5.7% complete response rate. The median survival ranged from 11.2 to 11.9 months.

From the five clinical trials in patients with advanced epithelial ovarian cancer, the adverse reaction profile from these 281 patients is similar to larger populations studied for metastatic breast cancer (see ADVERSE REACTIONS section).

Prostate Cancer

The safety and efficacy of TAXOTERE in combination with prednisone or prednisolone in patients with androgen-independent (hormone-refractory) metastatic prostate cancer were evaluated in a randomized multicenter Phase III trial. A total of 1006 patients with KPS \geq 60 were randomized to the following treatment groups:

- TAXOTERE 75 mg/m² every 3 weeks for 10 cycles.
- TAXOTERE 30 mg/m² administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
- Mitoxantrone 12 mg/m² every 3 weeks for 10 cycles.

All 3 regimens were administered in combination with prednisone or prednisolone 5 mg twice daily, continuously. Patients who received TAXOTERE every three weeks demonstrated statistically significant longer overall survival compared to those treated with mitoxantrone. The increase in survival seen in the TAXOTERE weekly arm was not statistically significant compared to the mitoxantrone control arm. Efficacy endpoints for the TAXOTERE arms versus the control arm are summarized in the following table:

Table 15 - Efficacy of TAXOTERE in the Treatment of Patients with Androgen-Independent (Hormone-Refractory) Metastatic Prostate Cancer (Intent-to-Treat Analysis)

Endpoint	TAXOTERE 75 mg/m ² every 3 weeks	TAXOTERE 30 mg/m ² every week	Mitoxantrone 12 mg/m ² every 3 weeks
Number of patients	335	334	337
Median survival (months)	18.9	17.4	16.5
95% CI	(17.0-21.2)	(15.7-19.0)	(14.4-18.6)
Hazard ratio	0.761	0.912	--
95% CI	(0.619-0.936)	(0.747-1.113)	--
p-value†*	0.0094	0.3624	--
Number of patients	291	282	300
PSA response rate (%)	45.4	47.9	31.7
95% CI	(39.5-51.3)	(41.9-53.9)	(26.4-37.3)
p-value*	0.0005	<0.0001	--
Number of patients	153	154	157
Pain response rate (%)	34.6	31.2	21.7
95% CI	(27.1-42.7)	(24.0-39.1)	(15.5-28.9)
p-value*	0.0107	0.0798	--
Number of patients	141	134	137
Tumor response rate (%)	12.1	8.2	6.6
95% CI	(7.2-18.6)	(4.2-14.2)	(3.0-12.1)
p-value*	0.1112	0.5853	--
†Stratified log rank test			
*Threshold for statistical significance=0.0175			

No statistical differences were observed between treatment groups for Global Quality of Life.

Differences in efficacy were not identified between elderly patients and younger patients.

In patients treated with TAXOTERE every three weeks, the following TEAEs, regardless of relationship to TAXOTERE, occurred at rates $\geq 10\%$ higher in patients 65 years of age or greater compared to younger patients: anemia (71% vs. 59%), infection (37% vs. 24%), nail changes (34% vs. 23%), anorexia (21% vs. 10%), weight loss (15% vs. 5%) respectively.

Fatigue, all grades, was one of the most commonly reported TEAEs (regardless of relationship to TAXOTERE) in patients treated with TAXOTERE every three weeks, but grade 3-4 were experienced in only 1.6% of subjects < 65 years old, 6.3% in those ≥ 65 years, and 10.4% in those ≥ 75 years old. Similarly diarrhea, all grades, was also commonly reported, but the incidence of grade 3-4 diarrhea was much lower for each age category, 1.6%, 2.4% and 3.0% respectively. There was a similar pattern for the incidence of infection grade 3-4, in the three age categories the incidence was 4.0%, 6.7%, and 9.0%, respectively.

Squamous Cell Carcinoma of the Head and Neck

Three phase II studies were conducted in 96 patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. In these clinical trials TAXOTERE 100 mg/m² was given as a one-hour infusion every 3 weeks.

The overall response rate (ORR) for evaluable patients was 24 to 45% with 0 to 14% of complete responses (CR). The median duration of response was 19 to 21 weeks for two studies. The mean time to progression was 11 weeks for one study.

From these clinical trials in patients with squamous cell carcinoma of the head and neck, the adverse reaction profile from these patients is similar to large population studied for metastatic breast cancer (see ADVERSE REACTIONS section). There were no life-threatening serious or unexpected adverse reactions reported in these trials.

DETAILED PHARMACOLOGY

Pharmacodynamics

In vitro, docetaxel is active against several murine and human cell lines at low concentrations ranging from 4 to 35 ng/mL in liquid medium. In head-to-head comparisons, docetaxel was generally more cytotoxic than paclitaxel (1-12 fold). Cross-resistance to docetaxel was studied in 11 cell lines overexpressing the Multi-Drug Resistance (MDR) gene and exposed to various anticancer agents. In six of them, IC₅₀ values of docetaxel were identical for normal and resistant cells and therefore no cross-resistance was noted. Combination therapy of docetaxel with several reference antitumor drugs has been explored. No synergy was detected with cisplatin or doxorubicin. Additive effects were noted with vincristine. Synergistic effects were obtained with cyclophosphamide and 5-fluorouracil (5-FU).

In vivo, docetaxel was administered i.v. against tumors grafted in distal sites (generally subcutaneously), and several tumors were treated at advanced and metastatic stages. Docetaxel was able to induce the complete regressions of several advanced grafted murine solid tumors.

The activities were dose-related and obtained at dosages not toxic for the mice. Experimental antitumor activity was also tested against a panel of human tumor xenografts. Docetaxel exerted curative activities against ovarian and breast tumors and melanoma.

In human cancer xenograft models, capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.

Mechanism of Action: The interaction of docetaxel with microtubules and tubulin has been clearly established: 1 - docetaxel promotes the assembly of stable microtubules in the absence of cofactors, such as guanosine triphosphate and microtubule-associated proteins; 2 - docetaxel inhibits the depolymerization of microtubules. Such properties have already been observed for paclitaxel: both docetaxel and paclitaxel bind to microtubules with a stoichiometry of 1 molecule per tubulin dimer. Both compounds bind to the same site, although the affinity of docetaxel is 1.9-fold higher.

General Pharmacology

Autonomic and Central Nervous Systems: In rats, single administration of 1, 3 or 10 mg/kg docetaxel did not markedly affect the central nervous system. The studies carried out only revealed moderate, inconsistent sedative effects, the intensity of which was not dose-related. Docetaxel did not show any anticonvulsant or analgesic properties. In mice, docetaxel administered at doses of 3, 10 or 30 mg/kg had no effect on the duration of hexobarbital-induced sleep. Docetaxel has no specific effects on the autonomic nervous system.

Cardiovascular System: The effects of docetaxel on the cardiovascular system were studied in conscious or anaesthetised rats, conscious rabbits and conscious or anaesthetised dogs. The main pharmacological effects observed after administration of single doses of the drug are hypotension, a decrease in vascular resistance and tachycardia. These effects, the intensity of which was not dose-related, were observed in conscious or anaesthetised dogs but not in rats and rabbits. In the dog, they were accompanied by clinical signs subsequent to histamine release. It has been clearly shown that these effects were attributable to polysorbate 80, the vehicle used to solubilize docetaxel.

Respiratory System: In the anaesthetised guinea pig, docetaxel administered at doses of 0.3, 1 or 3 mg/kg did not change bronchopulmonary resistance or compliance. At 3 mg/kg, the test substance induced a 41% decrease in respiratory rate which was comparable to that caused by the vehicle alone.

Immune System: As opposed to many anticancer drugs, docetaxel has only moderate immunosuppressive activity. Indeed, *in vitro*, although docetaxel inhibits the proliferation of T-cells and production of lymphokine (interleukin 2 and 3) from concanavallin A stimulated T-lymphocytes ($IC_{50} = 10^{-7}$ M), it has little or no effect on macrophage activation and TNF generation. Furthermore, *in vivo*, docetaxel has a protective effect against *Listeria monocytogenes* infection and has no immunosuppressive activity towards *Klebsiella pneumoniae septicemia* when administered to mice at doses of 10 and 20 mg/kg.

Gastrointestinal and Genito-Urinary Systems: Docetaxel had no effect on intestinal transit in rats at doses of 1, 3 or 10 mg/kg. In mice, a 15% increase in transit (single dose of 50 mg/kg) or 23% decrease (20 mg/kg for 5 days) was not biologically significant.

In water-loaded rats, docetaxel at doses of 1, 3 or 10 mg/kg did not produce any changes in urine output, pH or urinary excretion of Na⁺, K⁺, Cl and protein.

Pharmacokinetics

The pharmacokinetics of docetaxel have been extensively studied in animals. In summary, it can be concluded that docetaxel is characterised by a multiphasic plasma kinetic profile, has good tissue distribution, and is extensively metabolised in the liver.

After intravenous administration, docetaxel is distributed to all tissues and organs except the brain where extremely low levels were found. It is also detected in the foetus, tumor tissue and milk. It is eliminated very rapidly, although at a slower rate from tumor tissue than from normal tissue. It is excreted mainly in the faeces after undergoing hepatic metabolism and excretion. Urinary excretion is very limited. The drug is not markedly absorbed from the gastrointestinal tract.

The studies conducted *in vivo* (identification of major metabolites in excreta) and *in vitro* (liver microsome preparations of various species) demonstrated that monooxygenase enzymes, in particular cytochrome P450 3A, play a leading role in docetaxel metabolism while conjugation reactions are very limited. Docetaxel binds strongly to plasma proteins in all the species studied, including humans. Lastly, in man, the metabolic profile of docetaxel is comparable to that of the species used in the toxicity studies.

A phase I study evaluating the effect of capecitabine on the pharmacokinetics of docetaxel and the effect of docetaxel on the pharmacokinetics of capecitabine was conducted in 26 patients with solid tumors. Capecitabine was found to have no effect on the pharmacokinetics of docetaxel (C_{max} and AUC) and docetaxel has no effect on the pharmacokinetics of 5'-DFUR.

A phase I study evaluating the pharmacokinetic profiles of docetaxel (TAXOTERE), doxorubicin and cyclophosphamide in combination therapy was conducted in 30 patients treated for advanced breast cancer. There was no statistically significant difference in docetaxel clearance when co administered with doxorubicin and cyclophosphamide (TAC), as compared to monotherapy data. Doxorubicin and cyclophosphamide area under the concentration-time curve and maximum plasma concentrations were compared across triple (TAC) and double (AC) (doxorubicin and cyclophosphamide) study treatments; no statistically significant difference was shown. Overall, no pharmacokinetic interaction was demonstrated in this study.

TOXICOLOGY

Docetaxel was evaluated in a battery of genotoxic assays *in vitro* and *in vivo*. Docetaxel was devoid of mutagenic activity in the bacterial reverse mutation test (Ames test) and in the hypoxanthineguaninephosphoribosyl-transferase (HGPRT) test in Chinese Hamster Ovary cells (CHO- K1). However, in the chromosome aberration test in CHO-K1 cells, docetaxel induced an increase in aneuploid cells but was found to be devoid of any clastogenic activity-In the *in vivo* micronucleus test, docetaxel induced an increase in the number of micronucleated polychromatic erythrocytes in bone marrow. The increase in the incidence of micronucleated, aneuploid and polyploidy cells may be related to the pharmacological activity of docetaxel which induces inhibition of microtubule depolymerization.

Toxicity studies are summarized in tables on the following pages.

Acute Toxicity

Table 16- Acute Toxicity

Species of Animal/ Strain	Number Animals/ Dose Group	Route and Period of Admin	Admin. Dose or Treatment (mg/m ² /day)	Results
Mouse/CD ₂ F ₁	10 M, 10 F	i.v.	0, 222, 285, 363 and 468	LD ₁₀ between 285 and 468 mg/m ² HNLD = 222 mg/m ² Clinical signs included non-extension and/or paresis of hind limbs from 222 mg/m ²
Mouse/CD ₂ F ₁	10 M, 10 F	i.v.	0, 192, 285, 363 and 468	<u>Males:</u> HNLD = 285 mg/m ² LD ₁₀ = 345 mg/m ² ; LD ₅₀ = 414 mg/m ² ; LD ₉₀ = 468 mg/m ² <u>Females:</u> HNLD between 192 and 285 mg/m ² Clinical signs included non-extension and/or paresis of hind limbs from 192 mg/m ²
Mouse/CD ₂ F ₁	10 M, 10 F (Interim Sacrifice of 5/sex/group on day 4)	i.v.	0, 30, 144, 285, 468	HNLD = 285 mg/m ² No NOEL observed Toxic effects: neurotoxic signs (axonal and myelin degeneration of the sciatic nerves, accompanied by non-extension of the hind-limbs); testicular changes; lympho-hematopoietic changes (including leucopenia and cortical atrophy of the thymus); body weight loss (neurotoxic and testicular changes were not reversible after 28 days in 468 mg/m ²)
Rat/SD	10M, 10F (Interim Sacrifice of 5/sex/group on day 4)	i.v.	0, 60, 120, 180 and 240	HNLD = 60 mg/m ² . No NOEL observed. <u>Reversible Toxic Effects:</u> Decreased body weights; leucopenia (lymphopenia/neutropenia); anemia (erythrocyte count, hemoglobin concentration, hematocrit). <u>Bone Marrow Hyperplasia:</u> Tissue atrophy of multiple organs. <u>Irreversible Toxic Effects:</u> Acute pulmonary changes (accumulation of alveolar macrophages, fibrosis of alveolar septa) - all doses, Testicular atrophy - 60/120 mg/m ²
Dog/Beagle	2M; 2F (Interim Sacrifice of 1/sex/group	i.v.	0, 15, 30, 70 and 140	HNTD = 15 mg/m ² ; TDL = 15 mg/m ² ; TDH = 30 mg/m ² ; LD ₅₀ = 50 mg/m ² <u>Transient Clinical Signs:</u> Subdued behavior; abnormal respiration; peripheral vasodilation including reddening of

Species of Animal/ Strain	Number Animals/ Dose Group	Route and Period of Admin	Admin. Dose or Treatment (mg/m ² /day)	Results
	on day 8)			the pinnae, gums, and snout (treated and controls). Diarrhea, red feces, tremors and head shaking (treated animals). <u>Toxic Effects:</u> Body weights, food consumption; packed cell volume, hemoglobin conc., erythrocyte counts; platelets; leucopenia; intestinal epithelium necrosis (all segments of the intestines); <u>At Lethal Doses:</u> Myelosuppression in sternum and femur; atrophy of the lymphoid organs; impaired kidney function. Recovery was complete at 15 and 30 mg/m ²

Subacute Toxicity

Table 17- Subacute Toxicity

Species of Animal/ Strain	Number Animals/ Dose Group	Route and Period of Administration	Admin. Dose or Treatment (mg/m ² /day)	Results
Mouse/CD ₂ F ₁	10 M, 10 F	i.v. daily for 5 days	0, 45, 54, 64.8, 78, 93.6 and 112.5	HNLD: 54 mg/m ² /day LD ₁₀ = 60.3 mg/m ² /day LD ₅₀ = 90.3 mg/m ² /day LD ₉₀ = 135.6 mg/m ² /day <u>Clinical Signs:</u> lethargy, decreased motor activity, ataxia, hair loss, blanching, hunched posture, non-extension/paresis of the hind limbs; body weights (first 2 weeks); local irritation at injection site (second and third weeks of observation).
Mouse/CD ₂ F ₁	10 M, 10 F	i.v. daily for 5 days	0, 6, 30, 60 and 90	Significant Observations: <u>30, 60 and 90 mg/m²/day dosages:</u> deaths (1M/3F and 3M/1F, respectively); body weight loss; neurotoxic signs (axonal and myelin degeneration of the sciatic nerves); in RBC, WBC; in the myeloid to erythroid ratio with arrested maturation of the myeloid stem cells of the bone marrow; cortical atrophy of the thymus and changes in some other myeloid tissues; arrested maturation of the germ cells in the testes and ovaries (Effects seen to a lesser extent in the 30 and 60 mg/m ² /day dosages). These effects on reproductive organs were not reversed after the 28 day observation period. <u>6 mg/m²/day:</u> Slight reduction in lymphocyte count

Table 18- Subchronic and Chronic Toxicity

Species of Animal/ Strain	Number Animals/ Dose Group	Route and Period of Administration	Admin. Dose or Treatment (mg/m ² /day)	Results
Rat/Sprague-Dawley	10M, 10F	i.v. daily for 28-31 days	0, 0.3, 0.6 and 1.2	NOEL: 0.3 mg/m ² /day <u>Toxic Effects</u> (confined to 1.2 mg/m ²): slight food consumption (week 4, females); slight RBC, WBC, thrombocytes; slight ALAT, ASAT, ALP; testis weights; mild, diffuse degeneration of the seminiferous tubules accompanied by moderate hypospermatogenesis (1 male).
Rat/Sprague-Dawley	15M, 15F	i.v. single dose every 3 weeks for 6 weeks	0, 15, 30 and 60	<u>Reversible Effects</u> : Body weight and food consumption; Lympho-hematopoietic changes (including RBC, WBC, platelet and reticulocyte counts; bone marrow hypocellularity; thymic and lymph nodes atrophy at 60 mg/m ²); abnormal mitosis/single cell necrosis in multiple organs. <u>Effects not reversible after 28 days</u> : Testicular changes characterized by degeneration of seminiferous tubular epithelium (60 mg/m ² /day)
Rat/Sprague-Dawley	15M, 15F	i.v. single dose every 3 weeks for 6 months	0, 1.2, 6 and 30 (plus additional saline control)	NOEL 0.2 mg/kg Reversible lympho-hematopoietic changes as characterized above (thymic and lymph node atrophy not observed). Testicular effects (as above) had not recovered after the 1-month recovery period.
Dog (Beagle)	2M, 2F	i.v. daily for 5 days	0, 3, 6, and 15	HNTD = 3; TDL = 6; LD ₁₀₀ = 15 mg/m ² ; <u>15 mg/m²</u> : Body Weight/Food consumption; peripheral vasodilation (both treated and controls); emesis, diarrhea, moulting; lympho-hematopoietic changes (including, RBC, WBC, hemoglobin, platelet counts; fibrinogen; bone marrow atrophy in femur/sternum; atrophy of lymph node and white pulp of the spleen; cortical and medullary necrosis of thymus; intestinal epithelium necrosis (all segments of intestines) at lethal doses.
Dog (Beagle)	2M, 2F	i.v. single dose every 3 wks. for 12 wks	0, 7.5, 15 and 30	HNTD= 7.5; TDL = 15; TDH = 30 mg/m ² ; body weight/food consumption (30 mg/m ²); peripheral vasodilatation (treated/controls); blood in feces (15 and 30); slight to moderate leukocyte count (30 mg/m ²) - reversible in 2 weeks
Dog (Beagle)	5M, 5F	i.v. single dose every 3 wks. for 28 wks.	0, 2, 7.5 and 30	HNTD= 2; TDL= 7.5; TDH= 30 mg/m ² <u>At 30 mg/m²</u> : erythema; edema (all doses including controls) more prevalent in this dose after 3rd cycle; diarrhea; vomitus (containing blood); alopecia; body weight/food consumption; ECG changes; reversible leukocyte and platelet counts, RBC; ASAT, ALP; hypoplasia of bone marrow (30 mg/m ²); gastrointestinal changes; single-cell necrosis of epididymis and exocrine pancreas (females) at 7.5 and 30; <u>At high dose</u> : "clear" cell changes of the hepatocytes

Reproduction / Teratology

Table 19- Fertility and General Reproductive Performance

Species of Animal/ Strain	Number Animals/ Group	Route and Period of Administration	Admin. Dose of Treatment (mg/m ² /day)	Results
(Segment I) Rat/Sprague-Dawley	25M, 25F (add. 18F controls and 12F treated for hematology evaluation)	i.v. Males: 61 to 70 days prior mating Females: 15 days prior to mating until day 7 of gestation	Males: 0, 0.3, 0.9 and 1.7 (1.8) Females: 0, 0.3, 0.9 and 1.8 (1.35) ()=reduced dose	<u>NOEL</u> Males: 0.5 mg/m ² ; Females: <0.5 mg/m ² <u>Repro. NOEL</u> : Males: 0.15 mg/m ² ; Females 0.05 mg/m ² <u>Development NOEL</u> : 0.05 mg/m ² <u>Paternal Toxicity</u> : body weight and food consumption (mid- and high-dose); hematological changes. No histopathological changes in testis or epididymides. <u>Maternal Toxicity</u> : body weight and food consumption; hematological changes. <u>Reproductive Performance</u> : slight prolonged cohabitation at high dose.

Table 20 – Teratology

Species of Animal/ Strain	Number Animals/ Group	Route and Period of Administration	Admin. Dose of Treatment (mg/m ² /day)	Results
(Segment II) Rat/ Sprague-Dawley	ca. 20 mated females	i.v. days 6 to 17 of gestation	0, 0.18, 0.6 and 1.8	<u>Maternal Toxicity</u> : body weight gains and food consumption with intrauterine mortality; litter size. <u>F₁ Generation</u> : fetal body weight; delay in fetal ossification; at high dose: delay in development (physical, functional, and behavioral); no effect on reproductive performance. No teratogenic effects at doses tested.
(Segment II) Rat/ Sprague-Dawley	ca. 20 mated females	i.v. days 6 to 18 of gestation	0, 0.36, 1.2, 2.4, and 3.6	<u>Maternal Toxicity</u> : 3.6 and 2.4 mg/m ² , severe toxicity (mortality, abortion, body weight loss, RBC, WBC, and platelets) with no fetal evaluation due to mortality. At 1.2 mg/m ² : body weight and food consumption; platelets. <u>F₁ Generation</u> : fetal body weight (at 1.2 mg/m ²); delay in fetal ossification (at 1.2 and slightly at 0.36 mg/m ²) No teratogenic effects

Table 21 - Peri- and Post-Natal

Species of Animal/ Strain	Number Animals/ Group	Route and Period of Administration	Admin. Dose of Treatment (mg/m ² /day)	Results
(Segment III) Rat/ Sprague-Dawley	28-32 mated females	i.v. Gestation day 15 to day 21 post-partum	0, 0.24, 0.6 and 1.5	<u>F₀ Generation</u> : Maternal toxicity at 1.5 mg/m ² (body weight gains and food consumption) <u>F₁ Generation</u> : Slight delay in physical and functional development at 1.5 mg/m ² <u>F₂ Generation</u> : No development changes observed

Mutagenicity /Genotoxicity

Table 22 - Mutagenicity and Genotoxicity

Test	Test System	Route (mode) and Period of Admin.	Treatment Concentration (g/plate)	Results
Gene Mutation	<i>S. typhimurium</i> (TA 1535; TA 1537; TA 1538; TA 98 and TA 100)	Direct method (without/with metabolic activation)	62.5 - 1000 62.5 - 1000	Negative Negative
Gene Mutation	<i>E. coli</i> (wp2uvra)	Direct method (without/with metabolic activation)	62.5 - 1000 62.5 - 1000	Negative Negative
Chromosome aberration	CHO-K1 cells	Direct method (without/with metabolic activation)	0.5 - 2.0 0.1 - 1.0	Negative Negative
Micronucleus	CHO-K1 cells	Direct method (without/with metabolic activation)	0.15 - 1.2 0.15 - 1.2	Increase in micronucleated cells
Phase Distribution	CHO-K1 cells	Direct method	0.05 - 1.0	Appearance of aneuploid cells
HPRT	CHO-K1 cells	Direct method (without/with metabolic activation)	0.005 - 5 0.005 - 5	Negative Negative
Micronucleus (Bone marrow)	Mouse	i.v. - 2 doses, 24 h apart	0.195 - 7.2 mg/kg	Positive

REFERENCES

For the Safe Handling of Cytotoxic Agents:

1. OSHA Work-Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs. *Am J Hosp Pharm* 1986; 43(5):1193-1204.
2. American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. *Am J Hosp Pharm* 1990; 47(95):1033-49.
3. AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. *JAMA* 1985;253(11):1590-2
4. Oncology Nursing Society Clinical Practice Committee. Cancer Chemotherapy Guidelines. Module II - Recommendations of Nursing Practice in the Acute Care Setting. ONS, 1988; 2-14

Selected Papers:

1. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a taxol analogue. *Cancer Res* 1991;51:4845-52.
2. Bissery MC, Nohynek G, Sanderink GJ, *et al.* Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. *Anti-Cancer Drugs* 1995;6:339-55.
3. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of Docetaxel (Taxotere): Efficacy as a single agent and in combination. *Semin Oncol* 1995;22(6 Suppl 13): 3-16.
4. Bissery MC. Preclinical pharmacology of docetaxel. *Eur J Cancer* 1995;31A(Suppl 4):S1-S4.
5. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). *Cancer Surveys* 1993;17:305-13.
6. Catimel G, Werweij J, Mattijssen V, *et al.* Docetaxel (Taxotere). An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. *Ann Oncol* 1994;5:533-7.
7. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. *Clin Pharmacokinet* 1999;32(2):99-114.
8. Cortes JE, Pazdur R. Review article: Docetaxel. *J Clin Oncol* 1995;13(10):2643-55.
9. Dreyfuss AI, Clark JR, Norris CM, *et al.* Docetaxel: an active drug for squamous cell carcinoma of the head and neck. *Clin Oncol* 1996;14 (5):1672-8.
10. Eisenhauer EA, Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. *Eur J Cancer* 1995;31A (suppl 4): S11-S13.
11. Engels *et al.* Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. *Clinical Pharmacology and Therapeutics* 2004, 75 (5):448-54.
12. Fossella FV, Lee JS, Berille J, *et al.* Summary of phase II data of docetaxel (Taxotere), an active in the first- and second-line treatment of non-small-cell lung cancer. *Semin Oncol* 1995; 22 (2 suppl 4): 22-29.
13. Gralla RJ, Cole JT, Robertson CN, *et al.* Docetaxel plus cisplatin: an active combination regimen in non-small-cell lung cancer. *Oncol* 1997;(Suppl 7):27-30.
14. Guénard D, Guéritte-Voegelein F, Potier P. Taxol and Taxotere: Discovery, chemistry, and structure-activity relationships. *Acc Chem Re* 1993;26:160-7.

15. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, von Hoff DD. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted tumour cells. *Anticancer Drugs*;1992;3:121-4.
16. Kaye SB, Piccart M, Aapro M, *et al.* Docetaxel in advanced ovarian cancer: Preliminary results from three Phase II trials. *Eur J Cancer* 1995;31A(Suppl 4): S14-S17.
17. Kaye SB, Piccart M, Aapro M, *et al.* Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer: An updated overview. *Eur J Cancer* 1997;33(13):2167-70.
18. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. *Cancer Chemother Pharmacol* 1992;30:40-450.
19. Ravdin PM, Valero V. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. *Semin Oncol* 1995;22(2 Suppl 4):17-21.
20. Rigas JR. Single agent docetaxel in previously untreated non-small-cell lung cancer. *Oncol* 1997;11(Suppl 7):17-21.
21. Ringel I, Horowitz S. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. *J Nat'l Cancer Inst* 1991;83:289-97.
22. Riou JF, Naudin A, Lavelle F. Effects of taxotere on murine and human tumor cell lines. *Biochem Biophys Res Comm* 1992;187:164-70.
23. TAXOTERE Expert Report - Ovarian Carcinoma. Data on file.
24. TAXOTERE Integrated Safety and Efficacy Summary - Breast Carcinoma. (December 1997). Data on file.
25. TAXOTERE Integrated Summary of Efficacy - Non-Small Cell Lung Carcinoma. Data on file.
26. Van Oosterom AT, Schriivers D. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part II: clinical experience. *Anti-Cancer Drugs* 1995; 6:356-68.
27. Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. *Seminars in Ophthalmology* 2007; 22: 151-3.
28. Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. *Optometry and Vision Science* 2003; 80: 277-9.

PART III: CONSUMER INFORMATION

P^rTAXOTERE[®]
(docetaxel for injection)

Concentrated Solution
80 mg/2.0 mL
20 mg/0.5 mL

Manufacturer's Standard

This leaflet is part III of a three-part "Product Monograph" published when the drug is approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about TAXOTERE. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

TAXOTERE is used as or for the:

- adjuvant treatment of patients with operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide
- advanced or metastatic breast cancer, as single agent, or in combination with doxorubicin; or in combination with capecitabine (Xeloda[®]) after failure of previous anti-cancer drugs
- advanced or metastatic non small cell lung cancer, as single agent or in combination with platinum derivatives
- metastatic ovarian cancer after failure of previous anti-cancer drugs
- metastatic prostate cancer in combination with prednisone or prednisolone
- recurrent or metastatic squamous cell carcinoma of the head and neck after failure of previous anti-cancer drugs

What it does:

Here's how TAXOTERE works: Every cell in your body contains a supporting structure (almost like a "skeleton"). If this "skeleton" is changed or damaged, the cell can't grow or reproduce.

TAXOTERE makes the "skeleton" in cells unnaturally stiff. The cancer cells then can no longer grow or reproduce.

When it should not be used:

TAXOTERE should not be used if:

- you have had an allergic reaction to docetaxel or to polysorbate 80 or any of the other ingredients in the product;
- you have a low white blood cell count (neutropenia);
- you have a severe liver disease;
- you are pregnant or breast-feeding.

What the medicinal ingredient is:

The active ingredient in TAXOTERE is docetaxel.

What the nonmedicinal ingredients are:

The non-active ingredients are polysorbate and ethanol.

What dosage forms it comes in:

TAXOTERE is available in a concentrated solution for injection, packaging in a vial of 20 mg/0.5 mL or 80 mg/2 mL.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

TAXOTERE should be given under the supervision of a doctor experienced in the use of anti-cancer drugs.

There is a higher risk of developing severe adverse reactions, which may be life-threatening, in patients with liver disease. TAXOTERE should not be used if you have liver disease.

TAXOTERE should not be used in patients with white blood cell (neutrophil) counts of less than 1,500 cells/mm³.

Fatal cases of enterocolitis (inflammation of the digestive tract) have been reported.

TAXOTERE may cause severe life-threatening allergic reactions which require immediate discontinuation of the drug.

An increase in new (second) cancers has happened in people treated with TAXOTERE alone, or together with certain other anticancer treatments. This includes blood cancers, such as acute myeloid leukemia. No studies have been conducted to assess the carcinogenic potential of TAXOTERE.

BEFORE your TAXOTERE injection, talk to your doctor if:

- you are pregnant or planning to get pregnant
- you have not taken your premedication as directed.
- you suffer from alcoholism, liver disease or epilepsy.
- you have been previously treated with a medicine called paclitaxel and have had an allergic reaction to it.
- you are already receiving treatments for cancer. Different types of cancer may develop from using TAXOTERE with certain other anticancer treatments.
- you have kidney problems or high levels of uric acid in your blood. If after TAXOTERE infusion, you suffer from pain in your side, or reduced amount or darkening of urine, tell your doctor immediately.

Patients receiving TAXOTERE may experience:

- Fluid retention: Your doctor will prescribe you medication to reduce the risk of having severe fluid retention.
- Low blood cell count: Your doctor will need to check your blood at regular visits while you are using this medicine. Be sure to go to all your appointments. Your doctor may decide to reduce your dose if your white blood cell count is low.
- Allergic reactions: Allergic reactions may occur within a few minutes following the initiation of TAXOTERE. Severe allergic reactions with severe rash, difficulty in breathing (bronchospasm), low blood pressure (hypotension) may occur. Your doctor will prescribe you medication to reduce the risk of having an allergic reaction.
- Nerve pain (peripheral neurotoxicity): Some people feel this pain as numbness, tingling, or burning in their hands and feet. This nerve pain is rarely severe and usually goes away after treatment is completed. In some cases, your doctor may decide to reduce your dose or stop your treatment.
- Rash: This usually occurs on the feet and hands, but may also appear on the arms, face or body. The rash is rarely serious, and it is rare for a patient to discontinue TAXOTERE therapy because of rash or other skin problems. In some cases, your doctor may decide to reduce your dose.

- An increase in new (second) cancers, including acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma (types of blood cancer) and renal cancer, may occur in patients who are treated with docetaxel alone or together with certain other anticancer treatments. These cancers may occur years after treatment with TAXOTERE.
- Tumor lysis syndrome, which may have the following symptoms: nausea, vomiting, confusion, delirium, seizures, pain in your side, reduced amount of urine, or darkening of urine. If this happens, contact your doctor immediately, as it can cause life-threatening kidney failure and heart problems.
- Severe skin problems: symptoms may include blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or without a rash, and you may also have flu-like symptoms such as fever, chills, or muscle aches. The rash may be red, scaly and widespread with bumps under the skin (including your skin folds, trunk and upper extremities) and you may have blisters accompanied by fever. If you develop severe skin reactions, tell your doctor immediately.
- Feeling drunk or intoxicated: you may feel the effects of the alcohol contained in TAXOTERE. This may impair your ability to drive or use machinery.

INTERACTION WITH THIS MEDICATION

Drugs that may interact with TAXOTERE include, but are not limited to:

- cyclosporine
- terfenadine
- ketoconazole
- erythromycin
- protease inhibitors (e.g. ritonavir, indinavir, nelfinavir, saquinavir)
- itraconazole
- clarithromycin
- nefazodone
- telithromycin
- voriconazole
- pain relievers
- sleep aids, such as diazepam or other medicines called “benzodiazepines”.

Tell your doctor if you are taking any medicine which has been prescribed for you or which you bought without a prescription.

PROPER USE OF THIS MEDICATION

How often will I get treated with TAXOTERE?

TAXOTERE is usually given in a 1-hour intravenous (IV) dose every 21 days. Every patient is different; your doctor will determine what dose of TAXOTERE is right for you and how often you should receive it.

Your doctor may prescribe TAXOTERE either alone or in combination with other anti-cancer drugs, such as doxorubicin, cyclophosphamide, platinum derivatives (cisplatin, carboplatin), capecitabine (Xeloda®), prednisone or prednisolone.

What do I need to do before each TAXOTERE treatment?

The administration of TAXOTERE requires you to take medication before each treatment begins. Every time you receive TAXOTERE, you will be asked to take some premedication; the purpose of this premedication is to reduce the fluid retention you may experience during treatment. Usually, the premedication consists of corticosteroid pills that are taken orally one day before each TAXOTERE treatment, on the same day of each treatment, and one day after each treatment. Your doctor or nurse will tell you exactly what premedication you need to take and for how long.

Your doctor may also decide to give you other medications to reduce the risk of infection.

If you forget to take your premedication as directed, make sure to tell your doctor or nurse before you get your TAXOTERE treatment.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

This medicine needs to be given on a fixed schedule. If you miss an appointment, call your doctor for instructions.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like many anti-cancer drugs, TAXOTERE may have side effects. Most of the side effects that occur with TAXOTERE are manageable. Occasionally, it is necessary to stop the treatment. If you **do** experience side effects, your doctor can give you a number of medications and explain techniques to help make you feel more comfortable.

The most common side effects are:

- Nausea, diarrhea, vomiting
- Fatigue
- Stomatitis: sores in the mouth
- Nail changes
- Low white blood cell count (neutropenia)
- Fever
- Hair Loss
- Weakness
- Rash
- Nerve pain
- Fluid retention
- Swelling at the injection site

Side effects with unknown frequencies are:

- Inflammation of muscles.

Low White Blood Cell Count: Your white blood cells protect your body against infection. There are three types of white blood cells; the most important in preventing infections are cells called neutrophils. Many anti-cancer drugs, including TAXOTERE, cause a temporary drop in neutrophils (a condition known as neutropenia); however, most people receiving TAXOTERE do not develop infections, even when they have neutropenia. Your doctor will be checking routinely your white blood count and will alert you if your white count is low.

Fever is one of the most common signs of infection. If you have a fever, make sure to tell your doctor or nurse immediately.

Hair Loss: Loss of the hair (including eyebrows, eyelashes, pubic hair, underarm hair and the hair on your head), which is known as alopecia, occurs in most patients taking TAXOTERE. Hair loss may happen shortly after treatment has begun. Your hair should grow back once you've finished the treatment. However, some patients may experience permanent hair loss. In the meantime, your doctor or nurse can probably refer you to a special store that carries turbans and wigs specifically for patients with cancer.

Weakness: Many patients receiving TAXOTERE experience a feeling of weakness during their treatment. If weakness is accompanied by joint or muscle pain, make sure to tell your doctor or nurse; your doctor can prescribe pain medication to help make you feel more comfortable.

Rash: Patients on TAXOTERE may develop a rash. This usually occurs on the feet and hands, but may also appear on the arms, face or body. The rash generally appears within a week after each

TAXOTERE treatment, and disappears again before the next treatment. The rash is rarely serious, and it is rare for a patient to discontinue TAXOTERE therapy because of rash or other skin problems.

Severe skin problems: symptoms may include blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or without a rash. The rash may be red, scaly and widespread with bumps under the skin (including your skin folds, trunk and upper extremities) and you may have blisters accompanied by fever. If you develop severe skin reactions, tell your doctor immediately.

Nerve Pain: Patients receiving TAXOTERE may experience nerve pain; some people feel this pain as numbness, tingling, or burning in their hands and feet. This nerve pain is rarely severe and usually goes away after treatment is completed. However, if you are bothered by nerve pain, make sure to tell your doctor or nurse; your doctor can prescribe pain medication to help make you feel more comfortable.

Fluid Retention: Fluid retention can occur in patients receiving TAXOTERE. It may begin as swelling on the legs. Your doctor will prescribe medication, which is important for you to take to reduce the likelihood that the fluid retention will be serious or cause your treatment to be discontinued.

Blurred vision: In case of vision problems, you should have a complete eye and vision examination. If cystoid macular edema (blurred vision due to swelling of the retina within the eye) is diagnosed, your doctor may stop your treatment.

When TAXOTERE is used in combination with capecitabine (Xeloda®), the frequency of side effects may differ. In particular, the risk of developing a rash of the hands and feet is increased. You should refer to your doctor for more details.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
	Only if severe	In all cases	
Common			
Muscle pain		√	

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
	Only if severe	In all cases	
Nerve pain such as numbness, tingling, or burning in their hands and feet		√	
Weakness	√		
Uncommon			
Allergic reactions such as trouble breathing, tightness in the throat, rash, hives, swelling of the lips or tongue or low blood pressure		√	
Fever or signs of infection, like redness or swelling at the injection site, a cough that brings up mucus, or a sore throat		√	
Cardiac problems with symptoms such as: chest pain, rapid or irregular heartbeat, dizziness, nausea, shortness of breath, loss of consciousness		√	
Liver problems such as loss of appetite, dark urine, light-colored stools, yellowing of the skin or eyes		√	
Kidney problems		√	
Persistent vomiting or diarrhea; abdominal pain.		√	
Visual disturbances		√	
New (second) cancers, including acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma and renal cancer.			√
Unknown frequency			

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
	Only if severe	In all cases	
Electrolyte imbalance: weakness, confusion, muscle pain or cramps, irregular heartbeat.		√	
Redness, swelling, itching at the site of a previous infusion following later treatment.		√	
Severe skin reaction, blistering, peeling or bleeding, red, scaly rash with bumps under the skin, which may be accompanied by flu-like symptoms.		√	
Pain in your side, reduced amount of urine, darkening of urine.		√	
Muscle inflammation		√	

This is not a complete list of severe side effects. If you have any unexpected effects while taking this drug, contact your doctor or pharmacist.

HOW TO STORE IT

The unopened vials should be stored between 2° and 25°C in their original packaging. Protect from light.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at:
www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
 - Fax toll-free to 1-866-678-6789, or
 - Mail to: Canada Vigilance Program
 Health Canada
 Postal Locator 1908C
 Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

Your doctor, pharmacist and nurse are always your best source of information about your condition and treatment. If you have additional questions or concerns, be sure to ask them.

This document plus the full product monograph, prepared for health professionals can be found at www.sanofi.ca or by contacting the sponsor, sanofi-aventis Canada Inc., at: 1-800-265-7927.

This leaflet was prepared by sanofi-aventis Canada Inc.

Last revised: June 15, 2020